Patent Application
20230251273
The invention relates generally to the fields of immunology and medicine. More particularly, the invention relates to compositions and methods for detecting ASC (Apoptosis-associated Speck-like protein containing a Caspase Activating Recruitment Domain (CARD)) activity, caspase-1, IL-18, IL-1β, NOD-like receptors (NLR) and Absent in Melanoma 2 (AIM2)-like receptors (ALR) and other inflammasome proteins in samples obtained from a mammal as biomarkers for neurological disorders such as multiple sclerosis (MS), stroke, mild cognitive impairment (MCI) or traumatic brain injury (TBI).
The contents of the electronic sequence listing (UNMI_014_03US_SeqList_ST26.xml; Size: 4,580 bytes; and Date of Creation: Nov. 3, 2022) are herein incorporated by reference in its entirety.
Multiple sclerosis (MS) is a progressive autoimmune disorder that affects the central nervous system (CNS). Pathologically, it is characterized by demyelination in the spinal cord and brain as well as the presence of inflammatory lesions (Compston A. The pathogenesis and basis for treatment in multiple sclerosis. Clin Neurol Neurosurg. 2004;106:246-8). Clinically, patients with MS present blurred vision, muscle weakness, fatigue, dizziness, as well as balance and gate problems (Compston A. The pathogenesis and basis for treatment in multiple sclerosis. Clin Neurol Neurosurg. 2004;106:246-8). In the United States, alone, there are 400,000 patients with MS and about 2 million patients worldwide (Compston A. The pathogenesis and basis for treatment in multiple sclerosis. Clin Neurol Neurosurg. 2004;106:246-8).
Since the 1960s immunoglobulin (Ig) G oligoclonal bands (OCB) have been used as a classic biomarker in the diagnosis of MS (Stangel M, Fredrikson S, Meinl E, Petzold A, Stuve O and Tumani H. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol. 2013;9:267-76). However, the specificity of IgG-OCB is only 61%, as a result, other diagnostic criteria is needed to clinically determine the diagnosis of MS (Teunissen CE, Malekzadeh A, Leurs C, Bridel C and Killestein J. Body fluid biomarkers for multiple sclerosis--the long road to clinical application. Nat Rev Neurol. 2015;11:585-96), yet CSF-restricted IgG-OCB is a good predictor for conversion from CIS to CDMS, independently of MRI (Tintore M, Rovira A, Rio J, Tur C, Pelayo R, Nos C, Tellez N, Perkal H, Comabella M, Sastre-Garriga J and Montalban X. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology. 2008;70:1079-83). Similar results have been obtained when analyzing IgM-OCB (Villar LM, Masjuan J, Gonzalez-Porque P, Plaza J, Sadaba MC, Roldan E, Bootello A and Alvarez-Cermeno JC. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002;59:555-9). An important area of research in the field of MS is the identification of suitable biomarkers to predict who is at risk of developing MS, biomarkers of disease progression or exacerbation, as well as biomarkers of treatment response and prognosis.
There are 17.5 million deaths related to cardiovascular disease every year, of which 6.7 million occur as a result of stroke.( Mendis S, Davis S and Norrving B. Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke. 2015;46:e121-2). Even though there have been some large studies of stroke biomarkers, there is yet to be a gold standard biomarker that is used in the care of stroke patients. There is still a need for a biomarker that offers high sensitivity and high specificity for stroke.
The US Center for Disease Control (“CDC) defines a traumatic brain injury (“TBI”) “as a disruption in the normal function of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury.” As of 2010, the CDC recorded 823.7 TBI-related emergency room visits, hospitalizations and deaths per 100,000 individuals in the US. (US Centers for Disease Control “Traumatic Brain Injury and Concussion Website. https://www.cdc.gov/traumaticbraininjury/index.html (as of 21 Jun. 2018)). An important area of research in the field of TBI is the identification of suitable biomarkers to at risk of developing TBI, biomarkers of disease diagnosis, progression or exacerbation, as well as biomarkers of treatment response and prognosis. Previous work on the inflammasome has indicated that inflammasome proteins can be used as biomarkers after traumatic brain injury. The inflammasome is a multiprotein complex of the innate immune response involved in the activation of caspase-1 and the processing of the inflammatory cytokines IL-1beta and IL18. The inflammasome contributes to the inflammatory response after injury to the brain and the spinal cord, among others.
A great deal of interest has been generated concerning the topic of a boundary or transitional state between normal aging and dementia, or Alzheimer disease (AD). This condition has received several descriptors including mild cognitive impairment (MCI), incipient dementia, and isolated memory impairment. Subjects with a mild cognitive impairment (MCI) have a memory impairment beyond that expected for age and education yet are not demented. These subjects are becoming the focus of many prediction studies and early intervention trials. However, the diagnostic criteria for MCI has not generally been elucidated and the presence of biomarkers is lacking.
Thus, presented herein for addressing the above identified needs are inflammasome components useful as biomarkers with high sensitivity and specificity for various neurological or psychiatric conditions and methods of their use.
In one aspect, provided herein is a method of evaluating a patient suspected of having multiple sclerosis (MS), the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with MS, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having MS if the patient exhibits the presence of the protein signature. In some cases, the patient is presenting with clinical symptoms consistent with MS. In some cases, the MS is relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), or progressive-relapsing MS (PRMS). In some cases, the biological sample obtained from the patient is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs). In some cases, the level of the at least one inflammasome protein in the protein signature is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein in the protein signature. In some cases, the at least one inflammasome protein is interleukin 18 (IL-18), IL-1beta, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof. In some cases, the at least one inflammasome protein comprises each of caspase-1, IL-18, IL-1beta and ASC. In some cases, the at least one inflammasome protein comprises ASC. In some cases, the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein. In some cases, the level of the at least one inflammasome protein in the protein signature is enhanced relative to the level of the at least one inflammasome protein in a biological sample obtained from a control. In some cases, the biological sample obtained from the control is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs). In some cases, the control is a healthy individual, wherein the healthy individual is an individual not presenting with clinical symptoms consistent with MS. In some cases, the at least one inflammasome protein comprises ASC, wherein the level of ASC is at least 50% higher than the level of ASC in the biological sample obtained from a control. In some cases, the level of the at least one inflammasome protein in the protein signature is enhanced relative to a pre-determined reference value or range of reference values. In some cases, the biological sample obtained from patient is serum and the patient is selected as having MS with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%. In some cases, the biological sample is serum and the patient is selected as having MS with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%. In some cases, the biological sample is serum and the patient is selected as having MS with a sensitivity of at least 90% and a specificity of at least 80%. In some cases, the at least one inflammasome protein comprises ASC. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Table 7. In some cases, the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
In another aspect, provided herein is a method of evaluating a patient suspected of having suffered a stroke, the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with stroke or a stroke-related injury, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having suffered from a stroke if the patient exhibits the presence of the protein signature. In some cases, the patient is presenting with clinical symptoms consistent with stroke, wherein the stroke is ischemic stroke, transient ischemic stroke or hemorrhagic stroke. In some cases, the biological sample obtained from the patient is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs). In some cases, the level of the at least one inflammasome protein in the protein signature is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein in the protein signature. In some cases, the at least one inflammasome protein is interleukin 18 (IL-18), IL-1beta, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof. In some cases, the at least one inflammasome protein comprises each of caspase-1, IL-18, IL-1beta and ASC. In some cases, the at least one inflammasome protein comprises ASC. In some cases, the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein. In some cases, the level of the at least one inflammasome protein in the protein signature is enhanced relative to the level of the at least one inflammasome protein in a biological sample obtained from a control. In some cases, the biological sample obtained from the control is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs). In some cases, the control is a healthy individual, wherein the healthy individual is an individual not presenting with clinical symptoms consistent with MS. In some cases, the at least one inflammasome protein comprises ASC, wherein the level of ASC in a serum sample obtained from the subject is at least 70% higher than the level of ASC in a serum sample obtained from a control. In some cases, the at least one inflammasome protein comprises ASC, wherein the level of ASC in a serum-derived EV sample obtained from the subject is at least 110% higher than the level of ASC in a serum-derived EV sample obtained from a control. In some cases, the level of the at least one inflammasome protein in the protein signature is enhanced relative to a pre-determined reference value or range of reference values. In some cases, the biological sample obtained from patient is serum and the patient is selected as having suffered a stroke with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%. In some cases, the biological sample is serum and the patient is selected as having suffered a stroke with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%. In some cases, the biological sample is serum and the patient is selected as having suffered a stroke with a sensitivity of at least 100% and a specificity of at least 95%. In some cases, the at least one inflammasome protein comprises ASC. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Table 8. In some cases, the biological sample obtained from patient is serum-derived EVs and the patient is selected as having suffered a stroke with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%. In some cases, the biological sample is serum-derived EVs and the patient is selected as having suffered a stroke with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%. In some cases, the biological sample is serum-derived EVs and the patient is selected as having suffered a stroke with a sensitivity of at least 100% and a specificity of at least 100%. In some cases, the at least one inflammasome protein comprises ASC. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Table 9. In some cases, the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
In yet another aspect, provided herein is a method of treating a patient diagnosed with multiple sclerosis (MS), the method comprising administering a standard of care treatment for MS to the patient, wherein the diagnosis of MS was made by detecting an elevated level of at least one inflammasome protein in a biological sample obtained from the patient. In some cases, the MS is relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), or progressive-relapsing MS (PRMS). In some cases, the standard of care treatment is selected from therapies directed towards modifying disease outcome, managing relapses, managing symptoms or any combination thereof. In some cases, the therapies directed toward modifying disease outcome are selected from beta-interferons, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, mitoxanthrone, ocrelizumab, alemtuzumab, daclizumab and natalizumab.
In still another aspect, provided herein is a method of treating a patient diagnosed with stroke or a stroke related injury, the method comprising administering a standard of care treatment for stroke or stroke-related injury to the patient, wherein the diagnosis of stroke or stroke-related injury was made by detecting an elevated level of at least one inflammasome protein in a biological sample obtained from the patient. In some cases, the stroke is ischemic stroke, transient ischemic stroke or hemorrhagic stroke. In some cases, the stroke is ischemic stroke or transient ischemic stroke and the standard of care treatment is selected from tissue plasminogen activator (tPA), antiplatelet medicine, anticoagulants, a carotid artery angioplasty, carotid endarterectomy, intra-arterial thrombolysis and mechanical clot removal in cerebral ischemia (MERCI) or a combination thereof. In some cases, the stroke is hemorrhagic stroke and the standard of care treatment is an aneurysm clipping, coil embolization or arteriovenous malformation (AVM) repair. In some cases, the elevated level of the at least one inflammasome protein is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein. In some cases, the level of the at least one inflammasome protein is enhanced relative to the level of the at least one inflammasome protein in a control sample. In some cases, the level of the at least one inflammasome protein is enhanced relative to a pre-determined reference value or range of reference values. In some cases, the at least one inflammasome protein is interleukin 18 (IL-18), apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof. In some cases, the at least one inflammasome protein is caspase-1, IL-18, and ASC. In some cases, the at least one inflammasome protein is ASC. In some cases, the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein. In some cases, the biological sample is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
In a still further aspect, provided herein is a method of evaluating a patient suspected of having traumatic brain injury (TBI), the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with TBI, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having TBI if the patient exhibits the presence of the protein signature. In some cases, the patient is presenting with clinical symptoms consistent with TBI. In some cases, the biological sample obtained from the patient is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs). In some cases, the level of the at least one inflammasome protein in the protein signature is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein in the protein signature. In some cases, the at least one inflammasome protein is interleukin 18 (IL-18), IL-1β, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof. In some cases, the at least one inflammasome protein comprises caspase-1. In some cases, the at least one inflammasome protein comprises ASC. In some cases, the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein. In some cases, the level of the at least one inflammasome protein in the protein signature is enhanced relative to the level of the at least one inflammasome protein in a biological sample obtained from a control. In some cases, the at least one inflammasome protein comprises caspase-1, wherein the level of caspase-1 is at least 50% higher than the level of caspase-1in the biological sample obtained from the control. In some cases, the at least one inflammasome protein comprises ASC, wherein the level of ASC is at least 50% higher than the level of ASC in the biological sample obtained from the control. In some cases, the biological sample obtained from the control is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs). In some cases, the control is a healthy individual, wherein the healthy individual is an individual not presenting with clinical symptoms consistent with TBI. In some cases, the level of the at least one inflammasome protein in the protein signature is enhanced relative to a pre-determined reference value or range of reference values. In some cases, the biological sample obtained from patient is serum and the patient is selected as having TBI with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%. In some cases, the biological sample is serum and the patient is selected as having TBI with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%. In some cases, the biological sample is serum and the patient is selected as having TBI with a sensitivity of at least 90% and a specificity of at least 80%. In some cases, the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%. In some cases, the at least one inflammasome protein comprises ASC. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Tables 11B, 12B, 14A, 16, 17 or 19. In some cases, the at least one inflammasome protein comprises caspase-1. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Tables 11A or 15.
In yet another aspect, provided herein is a method of evaluating a patient suspected of having a brain injury, the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with brain injury, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having brain injury if the patient exhibits the presence of the protein signature. In some cases, the patient is presenting with clinical symptoms consistent with brain injury. In some cases, the biological sample obtained from the patient is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs). In some cases, the level of the at least one inflammasome protein in the protein signature is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein in the protein signature. In some cases, the at least one inflammasome protein is interleukin 18 (IL-18), IL-1β, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof. In some cases, the at least one inflammasome protein comprises ASC. In some cases, the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein. In some cases, the at least one inflammasome protein comprises caspase-1. In some cases, the level of the at least one inflammasome protein in the protein signature is enhanced relative to the level of the at least one inflammasome protein in a biological sample obtained from a control. In some cases, the at least one inflammasome protein comprises ASC, wherein the level of ASC is at least 50% higher than the level of ASC in the biological sample obtained from the control. In some cases, the at least one inflammasome protein comprises caspase-1, wherein the level of caspase-1 is at least 50% higher than the level of caspase-1in the biological sample obtained from the control. In some cases, the biological sample obtained from the control is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs). In some cases, the control is a healthy individual, wherein the healthy individual is an individual not presenting with clinical symptoms consistent with brain injury. In some cases, the brain injury is selected from a traumatic brain injury, stroke, mild cognitive impairment or multiple sclerosis. In some cases, the level of the at least one inflammasome protein in the protein signature is enhanced relative to a pre-determined reference value or range of reference values. In some cases, the brain injury is traumatic brain injury (TBI). In some cases, the biological sample obtained from patient is serum and the patient is selected as having TBI with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%. In some cases, the biological sample is serum and the patient is selected as having TBI with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%. In some cases, the biological sample is serum and the patient is selected as having TBI with a sensitivity of at least 90% and a specificity of at least 80%. In some cases, the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%. In some cases, the at least one inflammasome protein comprises ASC. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Tables 11B, 12B, 14A, 16, 17 or 19. In some cases, the at least one inflammasome protein comprises caspase-1. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Tables 11A or 15. In some cases, the brain injury is mid cognitive impairment (MCI). In some cases, the biological sample obtained from patient is serum and the patient is selected as having MCI with a sensitivity of at least 75%, 80%, 85%, 90%, 95%, 99% or 100%. In some cases, the biological sample is serum and the patient is selected as having MCI with a specificity of at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100%. In some cases, the biological sample is serum and the patient is selected as having MCI with a sensitivity of at least 90% and a specificity of at least 70%. In some cases, the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%. In some cases, the at least one inflammasome protein comprises ASC. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Tables 22 or 23. In some cases, the at least one inflammasome protein comprises IL-18. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Tables 22 or 25. In some cases, the brain injury is multiple sclerosis (MS). In some cases, the biological sample obtained from patient is serum and the patient is selected as having MS with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%. In some cases, the biological sample is serum and the patient is selected as having MS with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%. In some cases, the biological sample is serum and the patient is selected as having MS with a sensitivity of at least 90% and a specificity of at least 80%. In some cases, the at least one inflammasome protein comprises ASC. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Table 7. In some cases, the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%. In some cases, the brain injury is stroke. In some cases, the biological sample obtained from patient is serum and the patient is selected as having suffered a stroke with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%. In some cases, the biological sample is serum and the patient is selected as having suffered a stroke with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%. In some cases, the biological sample is serum and the patient is selected as having suffered a stroke with a sensitivity of at least 100% and a specificity of at least 95%. In some cases, the at least one inflammasome protein comprises ASC. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Table 8. In some cases, the biological sample obtained from patient is serum-derived EVs and the patient is selected as having suffered a stroke with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%. In some cases, the biological sample is serum-derived EVs and the patient is selected as having suffered a stroke with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%. In some cases, the biological sample is serum-derived EVs and the patient is selected as having suffered a stroke with a sensitivity of at least 100% and a specificity of at least 100%. In some cases, the at least one inflammasome protein comprises ASC. In some cases, a cut-off value for determining the sensitivity, specificity or both is selected from Table 9. In some cases, the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
In a still further aspect, provided herein is a method of evaluating a patient suspected of having mild cognitive impairment (MCI) the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with MCI, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having MCI if the patient exhibits the presence of the protein signature. In some cases, the patient is presenting with clinical symptoms consistent with MCI. In some cases, the biological sample obtained from the patient is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs). In some cases, the level of the at least one inflammasome protein in the protein signature is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein in the protein signature. In some cases, the at least one inflammasome protein is interleukin 18 (IL-18), IL-1β, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof. In some cases, the at least one inflammasome protein comprises ASC. In some cases, the at least one inflammasome protein comprises IL-18. In some cases, the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein. In some cases, the level of the at least one inflammasome protein in the protein signature is enhanced relative to the level of the at least one inflammasome protein in a biological sample obtained from a control. In some cases, the at least one inflammasome protein comprises ASC, wherein the level of ASC is at least 50% higher than the level of ASC in the biological sample obtained from the control. In some cases, the at least one inflammasome protein comprises IL-18, wherein the level of IL-18 is at least 25% higher than the level of IL-18 in the biological sample obtained from the control.
Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
As used herein, “protein” and “polypeptide” are used synonymously to mean any peptide-linked chain of amino acids, regardless of length or post-translational modification, e.g., glycosylation or phosphorylation.
By the terms “Apoptosis-associated Speck-like protein containing a Caspase Activating Recruitment Domain (CARD)” and “ASC” is meant an expression product of an ASC gene or isoforms thereof, or a protein that shares at least 65%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity with ASC (e.g., NP_037390 (Q9ULZ3-1), NP_660183 (Q9ULZ3-2) or Q9ULZ3-3 in human or NP_758825 (BAC43754) in rat) and displays a functional activity of ASC. A “functional activity” of a protein is any activity associated with the physiological function of the protein. Functional activities of ASC include, for example, recruitment of proteins for activation of caspase-1 and initiation of cell death.
By the term “ASC gene,” or “ASC nucleic acid” is meant a native ASC-encoding nucleic acid sequence, genomic sequences from which ASC cDNA can be transcribed, and/or allelic variants and homologues of the foregoing. The terms encompass double-stranded DNA, single-stranded DNA, and RNA.
As used herein, the term “inflammasome” means a multi-protein (e.g., at least two proteins) complex that activates caspase-1. Further, the term “inflammasome” can refer to a multi-protein complex that activates caspase-1 activity, which in turn regulates IL-1β, IL-18 and IL-33 processing and activation. See Arend et al. 2008; Li et al. 2008; and Martinon et al. 2002, each of which is incorporated by reference in their entireties. The terms “NLRP 1 inflammasome”, “NALP 1 inflammasome”, “NLRP2 inflammasome”, “NALP2 inflammasome”, “NLRP3 inflammasome”, “NALP3 inflammasome”, “NLRC4 inflammasome”, “IPAF inflammasome” or “AIM2 inflammasome” mean a protein complex of at least caspase-1 and one adaptor protein, e.g., ASC. For example, the terms “NLRP1 inflammasome” and “NALP1 inflammasome” can mean a multiprotein complex containing NLRP1, ASC, caspase-1, caspase-11, XIAP, and pannexin-1 for activation of caspase-1 and processing of interleukin-1β, interleukin-18 and interleukin-33. The terms “NLRP2 inflammasome” and “NALP2 inflammasome” can mean a multiprotein complex containing NLRP2 (aka NALP2), ASC and caspase-1,while the terms “NLRP3 inflammasome” and “NALP3 inflammasome” can mean a multiprotein complex containing NLRP3 (aka NALP3), ASC and the terms “NLRC4 inflammasome” and “IPAF inflammasome” can mean a multiprotein complex containing NLRC4 (aka IPAF), ASC and caspase-1. Additionally, the term “AIM2 Inflammasome” can mean a multiprotein complex comprising AIM2, ASC and caspase-1.
As used herein, the phrase “sequence identity” means the percentage of identical subunits at corresponding positions in two sequences (e.g., nucleic acid sequences, amino acid sequences) when the two sequences are aligned to maximize subunit matching, i.e., taking into account gaps and insertions. Sequence identity can be measured using sequence analysis software (e.g., Sequence Analysis Software Package from Accelrys CGC, San Diego, CA).
By the phrases “therapeutically effective amount” and “effective dosage” is meant an amount sufficient to produce a therapeutically (e.g., clinically) desirable result; the exact nature of the result will vary depending on the nature of the disorder being treated. For example, where the disorder to be treated is SCI, the result can be an improvement in motor skills and locomotor function, a decreased spinal cord lesion, etc. The compositions described herein can be administered from one or more times per day to one or more times per week. The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the compositions of the invention can include a single treatment or a series of treatments.
As used herein, the term “treatment” is defined as the application or administration of a therapeutic agent described herein, or identified by a method described herein, to a patient, or application or administration of the therapeutic agent to an isolated tissue or cell line from a patient, who has a disease, a symptom of disease or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease, or the predisposition toward disease.
The terms “patient” “subject” and “individual” are used interchangeably herein, and mean a mammalian subject to be treated, such as, for example, human patients. In some cases, the methods of the invention find use in experimental animals, in veterinary applications, and in the development of animal models for disease, including, but not limited to, rodents including mice, rats, and hamsters, as well as primates.
As interchangeably used herein, “Absent in Melanoma 2” and “AIM2” can mean an expression product of an AIM2 gene or isoforms; or a protein that shares at least 65%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity with AIM2 (e.g., accession number(s) NX_014862, NP004824, XP016858337, XP005245673, AAB81613, BAF84731, AAH10940) and displays a functional activity of AIM2.
As interchangeably used herein, “NALP1” and “NLRP1” mean an expression product of an NALP1 or NLRP1 gene or isoforms; or a protein that shares at least 65%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity with NALP1 (e.g., accession number(s) AAH51787, NP_001028225, NP_127500, NP_127499, NP_127497, NP055737) and displays a functional activity of NALP1.
As interchangeably used herein, “NALP2” and “NLRP2” mean an expression product of an NALP2 or NLRP2 gene or isoforms; or a protein that shares at least 65%,, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity with NALP2 (e.g., accession number(s) NP_001167552, NP_001167553, NP_001167554 or NP_060322) and displays a functional activity of NALP2.
As interchangeably used herein, “NALP3” and “NLRP3” mean an expression product of an NALP3 or NLRP3 gene or isoforms; or a protein that shares at least 65%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%amino acid sequence identity with NALP3 (e.g., accession number(s) NP_001073289, NP_001120933, NP_001120934, NP_001230062, NP_004886, NP_899632, XP_011542350, XP_016855670, XP_016855671, XP_016855672 or XP_016855673) and displays a functional activity of NALP3.
As interchangeably used herein, “NLRC4” and “IPAF” mean an expression product of an NLRC4 or IPAF gene or isoforms; or a protein that shares at least 65%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid sequence identity with NLRC4 (e.g., accession number(s) NP_001186067, NP001186068, NP_001289433 or NP_067032) and displays a functional activity of NLRC4.
By the term “stroke” and “ischemic stroke” is meant when blood flow is interrupted to part of the brain or spinal cord. By the term “ischemic stroke” and “transient ischemic stroke” is meant when blood flow is interrupted to part of the brain or spinal cord by blockage of an artery that supplies oxygen-rich blood to the brain or spinal cord. By the term “hemorrhagic stroke” is meant when blood flow is interrupted to part of the brain or spinal cord when an artery in the brain or spinal cord leaks blood or ruptures.
By “traumatic injury to the CNS” is meant any insult to the CNS from an external mechanical force, possibly leading to permanent or temporary impairments of CNS function.
The term “antibody” is meant to include polyclonal antibodies, monoclonal antibodies (mAbs), chimeric antibodies, humanized antibodies, anti-idiotypic (anti-Id) antibodies to antibodies that can be labeled in soluble or bound form, as well as fragments, regions or derivatives thereof, provided by any known technique, such as, but not limited to, enzymatic cleavage, peptide synthesis or recombinant techniques. Such anti-ASC and anti-NLRP1 antibodies of the present invention are capable of binding portions of ASC and NLRP1, respectively, which interfere with caspase-1 activation.
Methods involving conventional molecular biology techniques are described herein. Such techniques are generally known in the art and are described in detail in methodology treatises such as Molecular Cloning: A Laboratory Manual, 3rd ed., vol. 1-3, ed. Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; and Current Protocols in Molecular Biology, ed. Ausubel et al., Greene Publishing and Wiley-Interscience, New York, 1992 (with periodic updates). Immunology techniques are generally known in the art and are described in detail in methodology treatises such as Advances in Immunology, volume 93, ed. Frederick W. Alt, Academic Press, Burlington, MA, 2007; Making and Using Antibodies: A Practical Handbook, eds. Gary C. Howard and Matthew R. Kaser, CRC Press, Boca Raton, FL, 2006; Medical Immunology, 6th ed., edited by Gabriel Virella, Informa Healthcare Press, London, England, 2007; and Harlow and Lane ANTIBODIES: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988.
Although compositions and methods similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable compositions and methods are described below. All publications, patent applications, and patents mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. The particular embodiments discussed below are illustrative only and not intended to be limiting.
Provided herein are compositions and methods for diagnosing or evaluating a patient suspected of having a brain injury. The method can comprise measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with the brain injury, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having the brain injury if the patient exhibits the presence of the protein signature. The brain injury can be any insult to a patient’s brain due to trauma, degeneration or congenital issues. The brain injury can be selected from multiple sclerosis (MS), stroke, Alzheimers Disease (AD), Parkinson’s Disease (PD), cognitive impairment (e.g., mild cognitive impairment (MCI)) or traumatic brain injury (TBI). In one embodiment, the brain injury is MS. In another embodiment, the brain injury is stroke. In yet another embodiment, the brain injury is TBI.. In still another embodiment, the brain injury is MCI.
In one embodiment, provided herein is a method for diagnosing or evaluating a patient of having multiple sclerosis (MS) comprising measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with MS, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having the MS if the patient exhibits the presence of the protein signature. The patient can present with clinical symptoms consistent with MS. Through use of the methods and compositions provided herein, the patient can be diagnosed with any type of MS known in the art. The MS can be relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), or progressive-relapsing MS (PRMS).
In another embodiment, provided herein is a method for diagnosing or evaluating a patient suspected of having suffered a stroke, the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with stroke or a stroke-related injury, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having suffered from a stroke if the patient exhibits the presence of the protein signature. The patient can present with any clinical symptoms known in the art consistent with stroke. The stroke can be ischemic stroke, transient ischemic stroke or hemorrhagic stroke.
In one embodiment, provided herein is a method for diagnosing or evaluating a patient of having traumatic brain injury (TBI) comprising measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with TBI, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having a TBI if the patient exhibits the presence of the protein signature. The patient can present with clinical symptoms consistent with TBI. Through use of the methods and compositions provided herein, the patient can be diagnosed with any type of TBI known in the art.
In one embodiment, provided herein is a method for diagnosing or evaluating a patient of having cognitive impairment. The cognitive impairment can be mild or severe. In one embodiment, the cognitive impairment is mild cognitive impairment (MCI). The method comprises measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with cognitive impairment (e.g., MCI), wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having a cognitive impairment (e.g., MCI) if the patient exhibits the presence of the protein signature. The patient can present with clinical symptoms consistent with cognitive impairment (e.g., MCI). Through use of the methods and compositions provided herein, the patient can be diagnosed with any type of cognitive impairment known in the art such as, for example, MCI. Examples of symptoms often displayed by subject’s affected with MCI can include forgetfulness (forget things more frequently and/or forget important events), lack of focus (lose train of thought), feel anxious or overwhelmed when making decisions, understanding instructions or planning things, trouble navigating familiar environments, and/or impulsivity and questionable judgment. Subjects with MCI may also experience depression, irritability, anxiety or apathy.
In one aspect of the invention, the method of diagnosing or evaluating a patient suspected of having a brain injury (e.g., MCI, TBI, stroke or MS) comprises determining the presence or absence of a protein signature associated with the brain injury based on the measured level, abundance, or concentration of one or more inflammasome proteins in a biological sample obtained from the patient or on the inflammasome protein profile prepared from a biological sample obtained from the patient. In certain embodiments, the protein signature comprises an elevated level of at least one inflammasome protein. The level of the at least one inflammasome protein in the protein signature may be enhanced relative to the level or percentage of the protein in a biological sample obtained from a control subject or relative to a pre-determined reference value or range of reference values as further described herein. The control subject can be a healthy individual. The healthy individual can be an individual who does not exhibit symptoms associated with the brain injury (e.g., MCI, TBI, stroke or MS). The protein signature may, in certain embodiments, comprise an elevated level at least one inflammasome proteins. Patients who exhibit the protein signature may be selected or identified as having the brain injury (e.g., MCI, TBI, stroke or MS).
In some embodiments, the measured level, concentration, or abundance of one or more inflammasome proteins in the biological sample is used to prepare an inflammasome protein profile, wherein the profile is indicative of the severity of the brain injury (e.g., MCI, TBI, stroke or MS). The inflammasome protein profile may comprise the level, abundance, percentage or concentration of one or more inflammasome proteins measured in the patient’s biological sample optionally in relation to the level, abundance, percentage or concentration of the one or more inflammasome proteins in a biological sample obtained from a control subject or in relation to a pre-determined value or range of reference values as described herein. The control subject can be a healthy individual. The healthy individual can be an individual who does not exhibit symptoms associated with the brain injury (e.g., MCI, TBI, stroke or MS).
The level, percentage or concentration of at least one inflammasome protein can be assessed at a single time point and compared to a pre-determined reference value or range of reference values or can be assessed at multiple time points and compared to a pre-determined reference value or to previously assessed values.
As used herein, “pre-determined reference value” or range of reference values can refer to a pre-determined value or range of reference values of the level or concentration of an inflammasome protein ascertained from a known sample. For instance, the pre-determined reference value or range of reference values can reflect the level or concentration of an inflammasome protein in a biological sample obtained from a control subject (i.e., healthy subject). The control subject may, in some embodiments, be age-matched to the patients being evaluated. The biological sample obtained from the patient and the control subject can both be the same type of sample (e.g., serum or serum-derived extracellular vesicles (EVs). Thus, in particular embodiments, the measured level, percentage or concentration of at least one inflammasome protein is compared or determined relative to the level, percentage or concentration of said at least one inflammasome protein in a control sample (i.e. obtained from a healthy subject). The control or healthy subject can be a subject that does not exhibit symptoms associated with the brain injury (e.g., MCI, TBI, stroke or MS).
In other embodiments, the pre-determined reference value or range of reference values can reflect the level or concentration of an inflammasome protein in a sample obtained from a patient with a known severity of a brain injury (e.g., MCI, TBI, stroke or MS) as assessed by clinical measures or post mortem analysis. A pre-determined reference value can also be a known amount or concentration of an inflammasome protein. Such a known amount or concentration of an inflammasome protein may correlate with an average level or concentration of the inflammasome protein from a population of control subjects or a population of patients with known levels of said brain injury. In another embodiment, the pre-determined reference value can be a range of values, which, for instance, can represent a mean plus or minus a standard deviation or confidence interval. A range of reference values can also refer to individual reference values for a particular inflammasome protein across various levels of brain injury (e.g., MCI, TBI, stroke or MS) severity. In certain embodiments, an increase in the level of one or more inflammasome proteins (e.g., ASC, caspase-1 or IL-18) relative to a pre-determined reference value or range of reference values is indicative of a more severe brain injury.
The at least one inflammasome protein detected or measured in any of the methods provided herein can be one or a plurality of inflammasome proteins. In one embodiment, the at least one inflammasome protein is a plurality of inflammasome proteins. The plurality can be at least or at most 2, 3, 4 or 5 inflammasome proteins. The at least one inflammasome protein or plurality of inflammasome proteins can be a component of any inflammasome known in the art, such as, for example, the NAPL1/NLRP1, NALP2/NLRP2, NALP3/NLRP3, IPAF/NLRC4 or AIM2 inflammasome. In one embodiment, the at least one inflammasome protein is apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, interleukin-18 (IL-18) or interleukin-1beta (IL-1beta). In one embodiment, the at least one inflammasome protein is apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC). In one embodiment, the at least one inflammasome protein is caspase-1. In one embodiment, the at least one inflammasome protein is IL-18.
The inflammasome proteins of the methods provided herein and other marker proteins can be measured in a biological sample by various methods known to those skilled in the art. For instance, proteins can be measured by methods including, but not limited to, liquid chromatography, gas chromatography, mass spectrometry, immunoassays, radioimmunoassays, immunofluorescent assays, FRET-based assays, immunoblot, ELISAs, or liquid chromatography followed by mass spectrometry (e.g., MALDI MS). One of skill in the art can ascertain other suitable methods for measuring and quantitating any particular biomarker protein of the invention.
In one embodiment, the at least one inflammasome protein or plurality of inflammasome proteins detected or measured in any of the methods provided herein can be detected or measured through the use of an immunoassay. The immunoassay can be any immunoassay known in the art. For example, the immunoassay can be an immunoblot, enzyme-linked immunosorbent assay (ELISA) or a microfluidic immunoassay. An example of a microfluidic immunoassay for use in the methods provided herein is the Simple Plex™ Platform (Protein Simple, San Jose, California).
Any immunoassay for use in the methods provided herein can utilize an antibody directed against an inflammasome protein. The inflammasome component can be a component of any inflammasome known in the art, such as, for example, the NAPL1, NALP2, NALP3, NLRC4 or AIM2 inflammasome. In one embodiment, the inflammasome protein is apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, interleukin-18 (IL-18) or interleukin-1beta (IL-1beta). In one embodiment, the inflammasome protein is apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC). In one embodiment, the inflammasome protein is caspase-1. In one embodiment, the inflammasome protein is IL-18. In one embodiment, the inflammasome protein is IL-1beta.
Any suitable antibody that specifically binds ASC can be used, e.g., a custom or commercially available ASC antibody can be used in the methods provided herein. The anti-ASC antibody can be an antibody that specifically binds to a domain or portion thereof of a mammalian ASC protein such as, for example a human or rat ASC protein. Examples of anti-ASC antibodies for use in the methods herein can be those found in US8685400, the contents of which are herein incorporated by reference in its entirety. Examples of commercially available anti-ASC antibodies for use in the methods provided herein include, but are not limited to 04-147 Anti-ASC, clone 2EI-7 mouse monoclonal antibody from MilliporeSigma, AB3607 - Anti-ASC Antibody from Millipore Sigma, orb194021 Anti-ASC from Biorbyt, LS-C331318-50 Anti-ASC from LifeSpan Biosciences, AF3805 Anti-ASC from R & D Systems, NBP1-78977 Anti-ASC from Novus Biologicals, 600-401-Y67 Anti-ASC from Rockland Immunochemicals, D086-3 Anti-ASC from MBL International, AL177 anti-ASC from Adipogen, monoclonal anti-ASC (clone o93E9) antibody, anti-ASC antibody (F-9) from Santa Cruz Biotechnology, anti-ASC antibody (B-3) from Santa Cruz Biotechnology, ASC polyclonal antibody - ADI-905-173 from Enzo Life Sciences, or A161 Anti-Human ASC - Leinco Technologies. The human ASC protein can be accession number NP_037390.2 (Q9ULZ3-1), NP_660183 (Q9ULZ3-2) or Q9ULZ3-3. The rat ASC protein can be accession number NP_758825 (BAC43754). The mouse ASC protein can be accession number NP_075747.3. In one embodiment, the antibody binds to a PYRIN-PAAD-DAPIN domain (PYD) or a portion or fragment thereof of a mammalian ASC protein (e.g. human or rat ASC). In this embodiment, an antibody as described herein specifically binds to an amino acid sequence having at least 65% (e.g., 65, 70, 75, 80, 85%) sequence identity with a PYD domain or fragment thereof of human or rat ASC. In one embodiment, the antibody binds to a C-terminal caspase-recruitment domain (CARD) or a portion or fragment thereof of a mammalian ASC protein (e.g. human or rat ASC). In this embodiment, an antibody as described herein specifically binds to an amino acid sequence having at least 65% (e.g., 65, 70, 75, 80, 85%) sequence identity with a CARD domain or fragment thereof of human or rat ASC. In another embodiment, the antibody is an antibody that specifically binds to a region of rat ASC, e.g., amino acid sequence ALRQTQPYLVTDLEQS (SEQ ID NO: 1) (i.e., residues 178-193 of rat ASC, accession number BAC43754). In this embodiment, an antibody as described herein specifically binds to an amino acid sequence having at least 65% (e.g., 65, 70, 75, 80, 85%) sequence identity with amino acid sequence ALRQTQPYLVTDLEQS (SEQ ID NO: 1) of rat ASC. In another embodiment, the antibody is an antibody that specifically binds to a region of human ASC, e.g., amino acid sequence RESQSYLVEDLERS (SEQ ID NO: 2). In this embodiment, an antibody as described herein specifically binds to an amino acid sequence having at least 65% (e.g., 65, 70, 75, 80, 85%) sequence identity with amino acid sequence RESQSYLVEDLERS (SEQ ID NO: 2) of human ASC.
Any suitable anti-NLRP1 antibody (e.g., commercially available or custom) can be used in the methods provided herein. Examples of anti-NLRP1 antibodies for use in the methods herein can be those found in US8685400, the contents of which are herein incorporated by reference in its entirety. Examples of commercially available anti-NLRP1 antibodies for use in the methods provided herein include, but are not limited to human NLRP1 polyclonal antibody AF6788 from R&D Systems, EMD Millipore rabbit polyclonal anti-NLRP1 ABF22, Novus Biologicals rabbit polyclonal anti-NLRP1 NB100-56148, Sigma-Aldrich mouse polyclonal anti-NLRP1 SAB1407151, Abcam rabbit polyclonal anti-NLRP1 ab3683, Biorbyt rabbit polyclonal anti-NLRP1 orb325922 mybiosource rabbit polyclonal anti-NLRP1 MBS7001225, R&D systems sheep polyclonal AF6788, Aviva Systems mouse monoclonal anti-NLRP1 oaed00344, Aviva Systems rabbit polyclonal anti-NLRP1 ARO54478_P050, Origene rabbit polyclonal anti-NLRP1 APO7775PU-N, Antibodies online rabbit polyclonal anti-NLRP1 ABIN768983, Prosci rabbit polyclonal anti-NLRP1 3037, Proteintech rabbit polyclonal anti-NLRP1 12256-1-AP, Enzo mouse monoclonal anti-NLRP1 ALX-804-803-C100, Invitrogen mouse monoclonal anti-NLRP1 MA1-25842, GeneTex mouse monoclonal anti-NLRP1 GTX16091, Rockland rabbit polyclonal anti-NLRP1 200-401-CX5, or Cell Signaling Technology rabbit polyclonal anti-NLRP1 4990. The human NLRP1 protein can be accession number AAH51787, NP_001028225, NP_055737, NP_127497, NP_127499, or NP_127500. In one embodiment, the antibody binds to a Pyrin, NACHT, LRR1-6, FIIND or CARD domain or a portion or fragment thereof of a mammalian NLRP1 protein (e.g. human NLRP1). In this embodiment, an antibody as described herein specifically binds to an amino acid sequence having at least 65% (e.g., 65, 70, 75, 80, 85%) sequence identity with a specific domain (e.g., Pyrin, NACHT, LRR1-6, FIIND or CARD) or fragment thereof of human NLRP1. In one embodiment, a chicken anti-NLRP1 polyclonal that was custom-designed and produced by Ayes Laboratories can be used. This antibody can be directed against the following amino acid sequence in human NLRP1: CEYYTEIREREREKSEKGR (SEQ ID NO: 3). In one embodiment, the antibody specifically binds to an amino acid sequence having at least 85% sequence identity with amino acid sequence SEQ ID NO: 3 or SEQ ID NO: 4.
Any suitable antibody that specifically binds caspase-1 can be used, e.g., a custom or commercially available, in the methods provided herein. Examples of commercially available anti-caspase-1 antibodies for use in the methods provided herein include: R&D Systems: Cat# MAB6215, or Cat#AF6215; Cell Signaling: Cat #3866, #225, or #4199; Novus Biologicals: Cat #NB100-56565, #NBPI-45433, #NB100-56564, #MAB6215, #AF6215, #NBP2-67487, #NBP2-15713, #NBP2-15712, #NBP1-87680, #NB120-1872, #NBP1-76605, or # H00000834-M01.
Any suitable antibody that specifically binds IL-18 can be used, e.g., a custom or commercially available, in the methods provided herein. Examples of commercially available anti-IL-18 antibodies for use in the methods provided herein include: R&D Systems: Cat# D044-3, Cat# D045-3, #MAB646, #AF2548, #D043-3, # MAB2548, MAB9124, # MAB91241, # MAB91243, MAB91244, or # MAB91242; Novus Biologicals: Cat #AF2548, # D043-3, # MAB2548, # MAB9124, # MAB91243, # MAB91244, # MAB91241, # D045-3, # MAB91242, or #D044-3.
Any suitable antibody that specifically binds IL-1beta can be used, e.g., a custom or commercially available, in the methods provided herein. Examples of commercially available anti-IL-18 antibodies for use in the methods provided herein include: R&D Systems: Cat# MAB601, Cat# MAB201, # MAB6964, # MAB601R, #MAB8406, or # MAB6215; Cell Signaling: Cat #31202, #63124, #12426, or #12507; Novus Biologicals: Cat #AF-201-NA, #NB600-633, #MAB201, #MAB601, #NBP1-19775, #NBP2-27345, #AB-201-NA, #NBP2-27342, #NBP2-67865, #NBP2-27343, #NBP2-27340, #NBP2-27340, #NB120-8319, #23600002, #MAB8406, #NB100-73053, #NB120-10749, or # MAB601R.
Methods for determining monoclonal antibody specificity and affinity by competitive inhibition can be found in Harlow, et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988, Colligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992, 1993), and Muller, Meth. Enzymol. 92:589-601, 1983, which references are entirely incorporated herein by reference.
Anti-inflammasome (e.g., Anti-ASC and anti-NLRP1) antibodies of the present invention can be routinely made according to methods such as, but not limited to inoculation of an appropriate animal with the polypeptide or an antigenic fragment, in vitro stimulation of lymphocyte populations, synthetic methods, hybridomas, and/or recombinant cells expressing nucleic acid encoding such anti-ASC or anti-NLRP1 antibodies. Immunization of an animal using purified recombinant ASC or peptide fragments thereof, e.g., residues 178-193 (SEQ ID NO: 1) of rat ASC (e.g., accession number BAC43754) or SEQ ID NO: 2 of human ASC, is an example of a method of preparing anti-ASC antibodies. Similarly, immunization of an animal using purified recombinant NLRP1 or peptide fragments thereof, e.g., residues MEE SQS KEE SNT EG-cys (SEQ ID NO: 4) of rat NALP1 or SEQ ID NO: 3 of human NALP1, is an example of a method of preparing anti-NLRP1 antibodies.
Monoclonal antibodies that specifically bind ASC or NLRP1 may be obtained by methods known to those skilled in the art. See, for example Kohler and Milstein, Nature 256:495-497, 1975; U.S. Pat. No. 4,376,110; Ausubel et al., eds., Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1987, 1992); Harlow and Lane ANTIBODIES: A Laboratory Manual Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988; Colligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992, 1993), the contents of which are incorporated entirely herein by reference. Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, GILD and any subclass thereof A hybridoma producing a monoclonal antibody of the present invention may be cultivated in vitro, in situ or in vivo.
In any of the methods provided herein, the “biological sample” can refer to any bodily fluid or tissue obtained from a patient or subject. A biological sample can include, but is not limited to, whole blood, red blood cells, plasma, serum, peripheral blood mononuclear cells (PBMCs), urine, saliva, tears, buccal swabs, CSF, CNS microdialysate, and nerve tissue. In one embodiment, the biological sample is CSF, saliva, serum, plasma, or urine. In certain embodiments, the biological sample is CSF. In another embodiment, the biological sample is serum-derived extracellular vesicles (EVs). The EVs can be isolated from serum by any method known in the art. It should be noted that a biological sample obtained from a patient or test subject can be of the same type as a biological sample obtained from a control subject.
In some instances, the methods provided herein can be capable of diagnosing or detecting a brain injury (e.g., MCI, stroke, MS or TBI) with a predictive success of at least about 70%, at least about 71%, at least about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, up to 100%.
In some instances, the methods provided herein can be capable of diagnosing or detecting a brain injury (e.g., MCI, stroke, MS or TBI) with a sensitivity and/or specificity of at least about 70%, at least about 71%, at least about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, up to 100%.
In one embodiment, the brain injury is MS such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MS with a sensitivity of at least 75, 80, 90%, 95%, 99% or 100%. In another embodiment, the brain injury is MS such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MS with a specificity of at least 75%, 80%, 85%, 90%, 95%, 99% or 100%. The pre-determined reference value for these embodiments can be the cut-off values shown in Table 7. In yet another embodiment, the brain injury is MS such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MS with a sensitivity of at least 90%, and a specificity of at least 80%. The pre-determined reference value for this embodiment can be the cut-off values shown in Table 7. In some cases, the range of reference values can be from about 300 pg/ml to about 340 pg/ml to attain a sensitivity of at least 90% and a specificity of at least 80%.
In one embodiment, the brain injury is stroke such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has suffered a stroke with a sensitivity of at least 75, 80, 90%, 95%, 99% or 100%. In another embodiment, the brain injury is stroke such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MS with a specificity of at least 75%, 80%, 85%, 90%, 95%, 99% or 100%. The pre-determined reference value for these embodiments can be the cut-off values shown in Table 8. In another embodiment, the brain injury is stroke such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient suffered a stroke with a sensitivity of at least 100% and a specificity of at least 90%. The pre-determined reference value for this embodiment can be the cut-off values shown in Table 8. In some cases, the range of reference values can be from about 380 pg/ml to about 405 pg/ml to attain a sensitivity of at least 100% and a specificity of at least 90%. The stroke can be ischemic or hemorraghic as provided herein.
In one embodiment, the brain injury is stroke such that detection of an elevated level of ASC in serum-derived EVs obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has suffered a stroke with a sensitivity of at least 75%, 80%, 85%, 90%, 95%, 99% or 100%. In another embodiment, the brain injury is stroke such that detection of an elevated level of ASC in serum-derived EVs obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MS with a specificity of at least 75, 80, 90%, 95%, 99% or 100%. The pre-determined reference value for these embodiments can be the cut-off values shown in Table 9. In another embodiment, the brain injury is stroke such that detection of an elevated level of ASC in serum-derived EVs obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient suffered a stroke with a sensitivity of at least 100% and a specificity of at least 90%. The pre-determined reference value for this embodiment can be the cut-off values shown in Table 9. In some cases, the range of reference values can be from about 70 pg/ml to about 90 pg/ml to attain a sensivity of at least 100% and a specificity of at least 90%. The stroke can be ischemic or hemorraghic as provided herein.
In one embodiment, the brain injury is TBI such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has TBI with a sensitivity of at least 75, 80, 90%, 95%, 99% or 100%. In another embodiment, the brain injury is TBI such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has TBI with a specificity of at least 75%, 80%, 85%, 90%, 95%, 99% or 100%. The pre-determined reference value for these embodiments can be the cut-off values shown in Table 16. In yet another embodiment, the brain injury is TBI such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has TBI with a sensitivity of at least 90%, and a specificity of at least 80%. The pre-determined reference value for this embodiment can be the cut-off values shown in Table 16. In some cases, the range of reference values can be from about 275 pg/ml to about 450 pg/ml to attain a sensitivity of at least 80% and a specificity of at least 70%.
In one embodiment, the brain injury is TBI such that detection of an elevated level of caspase-1 in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has TBI with a sensitivity of at least 75, 80, 90%, 95%, 99% or 100%. In another embodiment, the brain injury is TBI such that detection of an elevated level of caspase-1 in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has TBI with a specificity of at least 75%, 80%, 85%, 90%, 95%, 99% or 100%. The pre-determined reference value for these embodiments can be the cut-off values shown in Table 15. In yet another embodiment, the brain injury is TBI such that detection of an elevated level of caspase-1 in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has TBI with a sensitivity of at least 90%, and a specificity of at least 80%. The pre-determined reference value for this embodiment can be the cut-off values shown in Table 15. In some cases, the range of reference values can be from about 2.812 pg/ml to about 1.853 pg/ml to attain a sensitivity of at least 70% and a specificity of at least 75%.
In one embodiment, the brain injury is MCI such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MCI with a sensitivity of at least 75%, 80%, 85%, 90%, 95%, 99% or 100%. In another embodiment, the brain injury is MCI such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MCI with a specificity of at least 50%, 55%, 60% 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100%. The pre-determined reference value for these embodiments can be the cut-off values shown in Tables 22 and 23. In yet another embodiment, the brain injury is MCI such that detection of an elevated level of ASC in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MCI with a sensitivity of at least 90%, and a specificity of at least 70%. The pre-determined reference value(s) for this embodiment can be the cut-off values shown in Tables 22 and 23. In some cases, the range of reference values can be about 257 pg/ml to about 342 pg/ml to attain a sensitivity of at least 90% and a specificity of at least 70%.
In one embodiment, the brain injury is MCI such that detection of an elevated level of IL-18 in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MCI with a sensitivity of at least 75%, 80%, 85%, 90%, 95%, 99% or 100%. In another embodiment, the brain injury is MCI such that detection of an elevated level of IL-18 in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MCI with a specificity of at least 50%, 55%, 60%, 65%, 75%, 80%, 85%, 90%, 95%, 99% or 100%. The pre-determined reference value for these embodiments can be the cut-off values shown in Tables 22 and 25. In yet another embodiment, the brain injury is MCI such that detection of an elevated level of IL-18 in serum obtained from the patient as compared to a control (e.g., a pre-determined reference value or range of reference values) as provided herein determines that the patient has MCI with a sensitivity of at least 70%, and a specificity of at least 55%. The pre-determined reference value for this embodiment can be the cut-off values shown in Tables 22 and 25. In some cases, the range of reference values from about 200 pg/ml to about 214 pg/ml to attain a sensitivity of at least 70% and a specificity of at least 50%.
In any of the methods provided herein, the sensitivity and/or specificity of an inflammasome protein (e.g., ASC) for predicting or diagnosing a brain injury (e.g., MCI, stroke, MS or TBI) is determined by calculation of area under curve (AUC) values with confidence intervals (e.g., 95%). The area under curve (AUC) can be determined from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
In one embodiment, the brain injury is MS such that detection of a level or concentration of at least one inflammasome protein in a biological sample obtained from the patient that is elevated by a pre-determined percentage over the level of the same at least one inflammasome protein in a biological sample obtained from a control subject is indicative of the patient as having MS. The biological sample obtained from the patient and the control subject can be of the same type (e.g., serum or serum-derived EVs). The pre-determined percentage can be about, at most or at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% 100%, 110%, 120%, 130%, 140% 150%, 160%, 170%, 180%, 190% or 200%. The at least one inflammasome protein can be selected from caspase-1, IL-18, IL-1beta and ASC. In one embodiment, the brain injury is MS such that detection of a level or concentration of ASC in serum obtained from the patient that is at least 50% higher than the level of ASC in a serum sample obtained from a control subject is indicative of the patient as having MS.
In one embodiment, the brain injury is stroke such that detection of a level or concentration of at least one inflammasome protein in a biological sample obtained from the patient that is elevated by a pre-determined percentage over the level of the same at least one inflammasome protein in a biological sample obtained from a control subject is indicative of the patient as having MS. The biological sample obtained from the patient and the control subject can be of the same type (e.g., serum or serum-derived EVs). The pre-determined percentage can be about, at most or at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% 100%, 110%, 120%, 130%, 140% 150%, 160%, 170%, 180%, 190% or 200%. The at least one inflammasome protein can be selected from caspase-1, IL-18, IL-1beta and ASC. In one embodiment, the brain injury is stroke such that detection of a level or concentration of ASC in serum obtained from the patient that is at least 70% higher than the level of ASC in a serum sample obtained from a control subject is indicative of the patient as having suffered a stroke. In one embodiment, the brain injury is stroke such that detection of a level or concentration of ASC in serum-derived EVs obtained from the patient that is at least 110% higher than the level of ASC in a serum-derived EVs sample obtained from a control subject is indicative of the patient as having suffered a stroke.
In one embodiment, the brain injury is TBI such that detection of a level or concentration of at least one inflammasome protein in a biological sample obtained from the patient that is elevated by a pre-determined percentage over the level of the same at least one inflammasome protein in a biological sample obtained from a control subject is indicative of the patient as having TBI. The biological sample obtained from the patient and the control subject can be of the same type (e.g., serum or serum-derived EVs). The pre-determined percentage can be about, at most or at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% 100%, 110%, 120%, 130%, 140% 150%, 160%, 170%, 180%, 190% or 200%. The at least one inflammasome protein can be selected from caspase-1, IL-18, IL-1beta and ASC. In one embodiment, the brain injury is TBI such that detection of a level or concentration of ASC in serum obtained from the patient that is at least 50% higher than the level of ASC in a serum sample obtained from a control subject is indicative of the patient as having TBI.
In one embodiment, the brain injury is MCI such that detection of a level or concentration of at least one inflammasome protein in a biological sample obtained from the patient that is elevated by a pre-determined percentage over the level of the same at least one inflammasome protein in a biological sample obtained from a control subject is indicative of the patient as having MCI. The biological sample obtained from the patient and the control subject can be of the same type (e.g., serum or serum-derived EVs). The pre-determined percentage can be about, at most or at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% 100%, 110%, 120%, 130%, 140% 150%, 160%, 170%, 180%, 190% or 200%. The at least one inflammasome protein can be selected from caspase-1, IL-18, IL-1beta and ASC. In one embodiment, the brain injury is MCI such that detection of a level or concentration of ASC in serum obtained from the patient that is at least 50% higher than the level of ASC in a serum sample obtained from a control subject is indicative of the patient as having MCI.
The present invention also provides a method of determining a prognosis for a patient with a brain injury (e.g., MCI, stroke, MS or TBI). In one embodiment, the method comprises providing a biological sample obtained from the patient and measuring the level of at least one inflammasome protein in the biological sample to prepare an inflammasome protein profile as described above, wherein the inflammasome protein profile is indicative of the prognosis of the patient. In some embodiments, an increase in the level of one or more inflammasome proteins (e.g., IL-18, NLRP1, ASC, caspase-1, or combinations thereof) relative to a pre-determined reference value or range of reference values is indicative of a poorer prognosis. For instance, an increase of about 20% to about 300% in the level of one or more inflammasome proteins relative to a pre-determined reference value or range of reference values is indicative of a poorer prognosis. In some cases, the inflammasome protein is ASC and the pre-determined reference values can be derived from Tables 7-9, 16, 22 or 23.
In other embodiments of the invention, the methods of diagnosing or evaluating a patient as having a brain injury (e.g., MCI, stroke, MS or TBI) further comprises administering a standard of care treatment for said brain injury (e.g., MCI, TBI, stroke or MS) to the patient based on the measured level of said at least one inflammasome protein or when a protein signature associated with a brain injury (e.g., MCI, stroke or MS or TBI) is identified. The methods of diagnosing or evaluating a patient as having a brain injury (e.g., MCI, stroke, MS or TBI) can be ascertained using the methods described herein. In some embodiment, the methods of diagnosing or evaluating a patient having a brain injury further comprises administering a neuroprotective treatment to the patient based on the measured level of said at least one inflammasome protein or when a protein signature associated with a brain injury or a more severe brain injury is identified. Such neuroprotective treatments include drugs that reduce excitotoxicity, oxidative stress, and inflammation. Thus, suitable neuroprotective treatments include, but are not limited to, methylprednisolone, 17alpha-estradiol, 17beta-estradiol, ginsenoside, progesterone, simvastatin, deprenyl, minocycline, resveratrol, and other glutamate receptor antagonists (e.g. NMDA receptor antagonists) and antioxidants. In some embodiments, neuroprotective treatments are antibodies against an inflammasome protein or binding fragments thereof, such as the antibodies directed against inflammasome proteins provided herein.
The success of, or response to, a standard of care treatment can also be monitored by measuring the levels of at least one inflammasome protein. Accordingly, in some embodiments, the methods of evaluating or diagnosing a patient with a brain injury (e.g., MCI, stroke, MS or TBI) further comprise measuring the level of at least one inflammasome protein in a biological sample obtained from the patient following treatment, preparing a treatment protein signature associated with a positive response to the treatment, wherein the treatment protein signature comprises a reduced level of at least one inflammasome protein, and identifying patients exhibiting the presence of the treatment protein signature as responding positively to the treatment. A reduction in the level, abundance, or concentration of one or more inflammasome proteins (e.g. ASC, IL-18 or caspase-1) is indicative of the efficacy of the treatment in the patient. The one or more inflammasome proteins measured in the sample obtained following treatment may be the same as or different than the inflammasome proteins measured in the sample obtained prior to treatment. The inflammasome protein levels may also be used to adjust dosage or frequency of a treatment. The inflammasome protein levels can be ascertained using the methods and techniques provided herein.
In one embodiment, the brain injury (e.g., MCI, TBI, stroke or MS) is MS and the standard of care treatment is selected from is selected from therapies directed towards modifying disease outcome, managing relapses, managing symptoms or any combination thereof. The therapies directed toward modifying disease outcome can be selected from beta-interferons, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, mitoxanthrone, ocrelizumab, alemtuzumab, daclizumab and natalizumab. wherein the stroke is ischemic stroke, transient ischemic stroke or hemorrhagic stroke.
In another embodiment, the brain injury (e.g., MCI, TBI, stroke or MS) is ischemic stroke or transient ischemic stroke and the standard of care treatment is selected from tissue plasminogen activator (tPA), antiplatelet medicine, anticoagulants, a carotid artery angioplasty, carotid endarterectomy, intra-arterial thrombolysis and mechanical clot removal in cerebral ischemia (MERCI) or a combination thereof. In still another embodiment, the brain injury (e.g., TBI, stroke or MS) is hemorrhagic stroke and the standard of care treatment is an aneurysm clipping, coil embolization or arteriovenous malformation (AVM) repair.
In another embodiment, the brain injury (e.g., MCI, TBI, stroke or MS) is TBI and the standard of care treatment is selected from diuretics, anti-seizure drugs, coma inducing drugs, surgery and/or rehabilitation. Diuretics can be used to reduce the amount of fluid in tissues and increase urine output. Diuretics, given intravenously to people with traumatic brain injury, can help reduce pressure inside the brain. An anti-seizure drug may be given during the first week to avoid any additional brain damage that might be caused by a seizure. Continued anti-seizure treatments are used only if seizures occur. Coma-inducing drugs can sometimes be used drugs to put people into temporary comas because a comatose brain needs less oxygen to function. This can be especially helpful if blood vessels, compressed by increased pressure in the brain, are unable to supply brain cells with normal amounts of nutrients and oxygen. The severity of the TBI can be assessed using the Glasgow Coma Scale. This 15-point test can help a doctor or other emergency medical personnel assess the initial severity of a brain injury by checking a person’s ability to follow directions and move their eyes and limbs. The coherence of speech can also provides important clues. Abilities are scored from three to 15 in the Glasgow Coma Scale. Higher scores mean less severe injuries.
In yet another embodiment, the brain injury (e.g., MCI, TBI, stroke or MS) is MCI and the standard of care treatment is selected from computerized cognitive training, group memory training, individual errorless learning sessions, family memory strategy interventions, DHA (docosahexaenoic acid), EPA (eicosapentanoic acid), ginko biloba, donepezil, rivastigimine, triflusal, Huannao Yicong capsules, piribedil, nicotine patch, vitamin E, vitamins B12 & B6, folic acid, rofecoxib, galantamine, cholinesterase inhibitors memantine, lithium, Wuzi Yanzong granules, ginseng, and exercise.
Also provided herein are kits for preparing an inflammasome protein profile associated with a brain injury (e.g., MCI, stroke, MS or TBI). The kits may include a reagent for measuring at least one inflammasome protein and instructions for measuring said at least one inflammasome protein for assessing the severity of a brain injury (e.g., MCI, stroke, MS or TBI) in a patient. As used herein, a “reagent” refers to the components necessary for detecting or quantitating one or more proteins by any one of the methods described herein. For instance, in some embodiments, kits for measuring one or more inflammasome proteins can include reagents for performing liquid or gas chromatography, mass spectrometry, immunoassays, immunoblots, or electrophoresis to detect one or more inflammasome proteins as described herein. In some embodiments, the kit includes reagents for measuring one or more inflammasome proteins selected from IL-18, ASC, caspase-1, or combinations thereof.
In one embodiment, the kit comprises a labeled-binding partner that specifically binds to one or more inflammasome proteins, wherein said one or more inflammasome proteins are selected from the group consisting of IL-18, ASC, caspase-1, and combinations thereof. Suitable binding partners for specifically binding to inflammasome proteins include, but are not limited to, antibodies and fragments thereof, aptamers, peptides, and the like. In certain embodiments, the binding partners for detecting ASC are antibodies or fragments thereof, The antibodies directed to ASC can be any antibodies known in the art and/or commercially available. Examples of anti-ASC antibodies for use in the methods provided herein are described herein. In certain embodiments, the binding partners for detecting ASC are antibodies or fragments thereof, aptamers, or peptides that specifically bind to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 of rat ASC and human ASC, respectively. In certain embodiments, the binding partners for detecting IL-18 are antibodies or fragments thereof. The antibodies to IL-18 can be any antibodies known in the art and/or commercially available, such as those, for example, provided herein. In certain embodiments, the binding partners for detecting caspase-1 are antibodies or fragments thereof. The antibodies to caspase-1 can be any antibodies known in the art and/or commercially available, such as those, for example, provided herein. In certain embodiments, the binding partners for detecting IL-1beta are antibodies or fragments thereof. The antibodies to IL-1beta can be any antibodies known in the art and/or commercially available, such as those, for example, provided herein. Labels that can be conjugated to the binding partner include metal nanoparticles (e.g., gold, silver, copper, platinum, cadmium, and composite nanoparticles), fluorescent labels (e.g., fluorescein, Texas-Red, green fluorescent protein, yellow fluorescent protein, cyan fluorescent protein, Alexa dye molecules, etc.), and enzyme labels (e.g., alkaline phosphatase, horseradish peroxidase, beta-galactosidase, beta-lactamase, galactose oxidase, lactoperoxidase, luciferase, myeloperoxidase, and amylase).
The present invention is further illustrated by the following specific examples. The examples are provided for illustration only and should not be construed as limiting the scope of the invention in any way.
Multiple sclerosis (MS) is an autoimmune disease that affects the brain and spinal cord. Important to the care of patients with MS is the need for biomarkers that can predict disease onset, disease exacerbation as well as response to treatment1.
The inflammasome is a key mediator of the innate immune response that in the CNS was first described to mediate inflammation after spinal cord injury2. The inflammasome is a multiprotein complex involved in the activation of caspase-1 and the processing of the pro-inflammatory cytokines IL-1β and IL-18 3.
In this example, the expression level of inflammasome proteins in serum samples from patients with MS are determined. Further, an examination of the sensitivity and specificity of inflammasome signaling proteins as biomarkers of MS was examined.
In this study, serum samples were analyzed from 120 normal donors and 32 patients that were diagnosed with MS. Samples were purchased from BioreclamationIVT. The normal donor group consisted of samples obtained from 60 male and 60 female donors in the age range of 20 to 70 years old. The age range in the MS group consisted of samples obtained from patients in the age range of 24 to 64 years old (
Concentration of inflammasome proteins ASC, IL-1β and IL-18 in serum was analyzed using a Simple Plex and a Simple Plex Explorer software. Results shown correspond to the mean of each sample run in triplicates. It should be noted that any system/instrument known in the art can be used to measure the levels of proteins (e.g., inflammasome proteins) in bodily fluids.
Prism 7 software (GraphPad) was used to analyze the data obtained from the Simple Plex Explorer Software. Comparisons between groups were carried after identifying outliers followed by determination of the area under the receiver operator characteristic (ROC) curve, as well as the 95% confidence interval (CI). The p-value of significance used was <0.05. Sensitivity and specificity of each biomarker was obtained for a range of different cut-off points. Samples that yielded a protein value below the level of detection of the assay were not included in the analyses for that analyte.
ROC curves are summarized as the area under the curve (AUC). A perfect AUC value is 1.0, where 100% of subjects in the population will be correctly classified as having MS or not. In contrast, an AUC of 0.5 signifies that subjects are randomly classified as either positive or negative for MS, which has no clinical utility. It has been suggested that an AUC between 0.9 to 1.0 applies to an excellent biomarker; from 0.8 to 0.9, good; 0.7 to 0.8 fair; 0.6 to 0.7, poor and 0.5 to 0.6, fail. 10
Serum samples from MS patients were analyzed and compared to serum from healthy/control individuals using a Simple Plex assay (Protein Simple) for the protein expression of the inflammasome signaling proteins caspase-1, ASC, IL-1β and IL-18 (
To then determine if these inflammasome signaling proteins have the potential to be reliable biomarkers for MS pathology, the area under the curve (AUC) for caspase-1 (
Furthermore, the cut-off point for ASC was 352.4 pg/ml with 84% sensitivity and 90% sensitivity (Table 2). For caspase-1, the cut-off point was 1.302 pg/ml with 89% sensitivity and 56% specificity (Table 2). Moreover, we found that in regards to ASC for a 100% sensitivity the cut-off point was 247.2 pg/ml with 58.26% specificity, and for 100% specificity, the cut-off point was 465.1 pg/ml and a 65.63% sensitivity. In the case of caspase-1, for 100% sensitivity, the cut-off point was 1.111 pg/ml with 44.44% specificity. For 100% specificity, the cut-off point was 2.718 pg/ml with 52.63% sensitivity. Thus, these findings indicate that caspase-1 and ASC can be biomarkers for MS.
In this study, a statistically significant higher level of IL-18 was detected in the serum of MS patients when compared to healthy subjects. In addition, the AUC for IL-18 in the cohort of patients was 0.7075 with a CI between 0.6052 to 0.8097 and a sensitivity of 84%, however, the specificity was only 44% when the cut-off point was 190.1 pg/ml. When the cut-off point was 104.2 pg/ml the sensitivity was 100% but the specificity was only 6.723%. Similarly, when the cut-off point was 427.2 pg/ml, the specificity was 100% but the sensitivity was only 15.63%.
Further, the levels of IL-1β were significantly lower in the MS group than the control group. The AUC was 0.7619 with a CI between 0.5806 to 0.9432. The sensitivity was 100% when the cut-off point was 0.825 with 62% specificity.
Higher protein levels of caspase-1 was also found in the serum of MS patients. Importantly, the AUC for caspase-1 was 0.848 with a CI between 0.703 to 0.9929. With a cut-off point of 1.302 pg/ml the sensitivity was 89% with 56% specificity. Moreover, with a 100% sensitivity the cut-off point was 1.111 pg/ml with 44.44% specificity; whereas with 100% specificity, the sensitivity was 52.63% with a cut-off point of 2.718 pg/ml.
Moreover, in this example, ASC was the most promising biomarker with an AUC of 0.9448 and a narrow CI between 0.9032 to 0.9864. A cut-off point of 352.4 pg/ml resulted in 84% sensitivity and 90% specificity. When the cut-off point was 247.2 pg/ml, the sensitivity was 100% and the specificity 58%.
Thus, based on these findings caspase-1 and ASC are promising biomarker with a high AUC value and a high sensitivity. Importantly, a combination of caspase-1 and ASC as biomarkers for MS with other diagnostic criteria may further increase the sensitivity of these biomarkers for MS beyond what is described in this example. Some clinically used biomarkers such as serum aquaporin 4 antibodies (AQP4-IgG), which is used to differentiate between patients with MS and patients with neuromyelitis optica, have a median sensitivity of 62.3% with a range between 12.5% to 100%, depending on the assay used for the measurements. 29
Since the 1960s immunoglobulin (Ig) G oligoclonal bands (OCB) have been used as a classic biomarker in the diagnosis of MS. 30 However, the specificity of IgG-OCB is only 61%, as a result, other diagnostic criteria is needed to clinically determine the diagnosis of MS, 31 yet CSF-restricted IgG-OCB is a good predictor for conversion from CIS to CDMS, independently of MRI 32. Similar results have been obtained when analyzing IgM-OCB. 33 Interestingly, IgG against measles, rubella and varicella zoster (MRZ) are present in the CSF of MS patients, thus MRZ-specific IgG have the potential to be used as biomarkers of MS diagnosis. 34
Importantly, in this study, caspase-1 and ASC have been identified as potential biomarkers of MS pathology with high AUC values; 0.9448 and 0.848, respectively with sensitivities above 80% and in the case of ASC a specificity of 90%.
The following references are incorporated by reference in their entireties for all purposes.
1. Compston A. The pathogenesis and basis for treatment in multiple sclerosis. Clin Neurol Neurosurg. 2004;106:246-8.
2. de Rivero Vaccari JP, Lotocki G, Marcillo AE, Dietrich WD and Keane RW. A molecular platform in neurons regulates inflammation after spinal cord injury. J Neurosci. 2008;28:3404-14.
3. de Rivero Vaccari JP, Dietrich WD and Keane RW. Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. J Cereb Blood Flow Metab. 2014;34:369-75.
4. Ming X, Li W, Maeda Y, Blumberg B, Raval S, Cook SD and Dowling PC. Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci. 2002;197:9-18.
5. Cao Y, Goods BA, Raddassi K, Nepom GT, Kwok WW, Love JC and Hafler DA. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci Transl Med. 2015;7:287ra74.
6. Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A, Desina G, Comi G, Flavell R, Su MS and Adorini L. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol. 1999;163:2403-9.
7. Inoue M, Williams KL, Gunn MD and Shinohara ML. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2012;109:10480-5.
8. Gris D, Ye Z, Iocca HA, Wen H, Craven RR, Gris P, Huang M, Schneider M, Miller SD and Ting JP. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol. 2010;185:974-81.
9. Brand FJ, 3rd, Forouzandeh M, Kaur H, Travascio F and de Rivero Vaccari JP. Acidification changes affect the inflammasome in human nucleus pulposus cells. J Inflamm (Lond). 2016;13:29.
10. Xia J, Broadhurst DI, Wilson M and Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013;9:280-299.
11. Dumas A, Amiable N, de Rivero Vaccari JP, Chae JJ, Keane RW, Lacroix S and Vallieres L. The inflammasome pyrin contributes to pertussis toxin-induced IL-1beta synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis. PLoS Pathog. 2014;10:e1004150.
12. Katsavos S and Anagnostouli M. Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Mult Scler Int. 2013;2013:340508.
13. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D′Alfonso S, Alvarez-Cermeno JC, Kleinova P, Horakova D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martinez AD, Carra A, Salvetti M, Uccelli A, Torkildsen O, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli O, Vecsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdova E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintore M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV and Giovannoni G. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler. 2015;21:1013-24.
14. Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72 Suppl 1:1-5.
15. Milo R and Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev. 2014;13:518-24.
16. Inoue M, Chen PH, Siecinski S, Li QJ, Liu C, Steinman L, Gregory SG, Benner E and Shinohara ML. An interferon-beta-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage. Nat Neurosci. 2016;19:1599-1609.
17. Inoue M, Williams KL, Oliver T, Vandenabeele P, Rajan JV, Miao EA and Shinohara ML. Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal. 2012;5:ra38.
18. Chen YC, Chen SD, Miao L, Liu ZG, Li W, Zhao ZX, Sun XJ, Jiang GX and Cheng Q. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J Neuroimmunol. 2012;243:56-60.
19. Losy J and Niezgoda A. IL-18 in patients with multiple sclerosis. Acta Neurol Scand. 2001;104:171-3.
20. Levesque SA, Pare A, Mailhot B, Bellver-Landete V, Kebir H, Lecuyer MA, Alvarez JI, Prat A, de Rivero Vaccari JP, Keane RW and Lacroix S. Myeloid cell transmigration across the CNS vasculature triggers IL-1beta-driven neuroinflammation during autoimmune encephalomyelitis in mice. J Exp Med. 2016;213:929-49.
21. Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojsavljevic N, Nicoletti F and Drulovic J. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol. 2009;207:101-6.
22. Hauser SL, Doolittle TH, Lincoln R, Brown RH and Dinarello CA. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 1990;40:1735-9.
23. Maimone D, Gregory S, Amason BG and Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991;32:67-74.
24. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N and Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci. 1991;104:230-4.
25. Huang WX, Huang P and Hillert J. Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult Scler. 2004;10:482-7.
26. de Rivero Vaccari JP, Dietrich WD and Keane RW. Therapeutics targeting the inflammasome after central nervous system injury. Transl Res. 2016;167:35-45.
27. de Rivero Vaccari JP, Lotocki G, Alonso OF, Bramlett HM, Dietrich WD and Keane RW. Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J Cereb Blood Flow Metab. 2009;29:1251-61.
28. Shaw PJ, Lukens JR, Burns S, Chi H, McGargill MA and Kanneganti TD. Cutting edge: critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis. J Immunol. 2010;184:4610-4.
29. Jarius S and Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23:661-83.
30. Stangel M, Fredrikson S, Meinl E, Petzold A, Stuve O and Tumani H. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol. 2013;9:267-76.
31. Teunissen CE, Malekzadeh A, Leurs C, Bridel C and Killestein J. Body fluid biomarkers for multiple sclerosis--the long road to clinical application. Nat Rev Neurol. 2015;11:585-96.
32. Tintore M, Rovira A, Rio J, Tur C, Pelayo R, Nos C, Tellez N, Perkal H, Comabella M, Sastre-Garriga J and Montalban X. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology. 2008;70:1079-83.
33. Villar LM, Masjuan J, Gonzalez-Porque P, Plaza J, Sadaba MC, Roldan E, Bootello A and Alvarez-Cermeno JC. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002;59:555-9.
34. Brettschneider J, Tumani H, Kiechle U, Muche R, Richards G, Lehmensiek V, Ludolph AC and Otto M. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One. 2009;4:e7638.
A biomarker is a characteristic that can be measured objectively and evaluated as an indicator of normal or pathologic biological processes9. Thus, in the context of stroke, biomarkers in blood or other body fluids can be used as indicators of stroke onset. However, to date, there is no biomarker available that is regularly used in the diagnosis and management of stroke. To this end, cytokines such as IL-10 or tumor necrosis factor as well as other inflammatory proteins such as C-reactive protein, high-mobility group box-1 or heat shock proteins have been considered as potential candidates for further biomarker analyses in stroke patients10-12.
In this example, a Simple Plex Assay (Protein Simple) was used to analyze serum and serum-derived EV samples from stroke patients and control donors for inflammasome protein levels of caspase-1, apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC), Interleukin (IL)-1beta. Receiver operator characteristic (ROC) curves and associated confidence intervals were calculated following analysis of the serum and serum-derived EV samples from patients after stroke and from healthy unaffected donors to measure sensitivity and specificity of inflammasome proteins to establish the potential of inflammasome signaling proteins as biomarkers of stroke.
Participants: In this example, serum samples from 80 normal donors and 16 patients that were diagnosed with stroke were analyzed. Samples were purchased from BioreclamationIVT. The normal donor group consisted of samples obtained from 40 male and 40 female donors in the age range of 46 to 70 years old. The age range in the stroke group consisted of samples obtained from patients in the age range of 46 to 87 years old (
By Total Exosome Isolation from Serum kit (Invitrogen): Total Exosome Isolation from serum was used according to the manufacturer’s instructions (Invitrogen). Briefly, 100 ul of each sample was centrifuged at 2000 xg for 30 minutes. The supernatant was then incubated with 20 ul of Total Exosome Isolation reagent for 30 minutes at 40 C followed by centrifugation at 10,000 xg for 10 minutes at room temperature. Supernatants were discarded and the pellet was resuspended in 50 ul of PBS.
By ExoQuick: EV were isolated from serum samples using ExoQuick (EQ, System Biosciences) as described in6. Briefly, 100 ul of each sample was centrifuged at 3,000 xg for 15 minutes. The supernatant was then incubated with 24.23 ul of ExoQuick Exosome Precipitation Solution (for serum) for 30 min at 40 C followed by centrifugation at 1,500 xg for 30 minutes. Supernatants were discarded and residual EQ solution was centrifuged at 1,500 xg for 5 minutes. The pellet was then resuspended in 50 ul of PBS.
To determine the protein concentration of caspase-1, ASC, IL-1β and IL-18 in serum and serum-derived EV, a Simple Plex assay was run and analyzed with Simple Plex Explorer software. Results shown correspond to the mean of each sample run in triplicates. It should be noted that any system/instrument known in the art can be used to measure the levels of proteins (e.g., inflammasome proteins) in bodily fluids.
To quantify the protein concentration in isolated EV, the Pierce Coomassie (Bradford) Protein Assay Kit (ThermoFisher Scienftific, Inc.) was used according to the manufacturer’s instructions. Serum-derived EV were lysed (1:1 dilution) in lysis buffer as described.6
EV were analyzed by NanoSight NS300 (Malvern Instruments Company, Nanosight, and Malvern, United Kingdom). Isolated exosomes were diluted in PBS (1:1000) for analysis, and three 90 second videos were then recorded. Data were analyzed using Nanosight NTA 2.3 Analytical Software (Malvern Instruments Company) with a detection threshold optimized for each sample and a screen gain set at 10 to track as many particles as possible while maintaining minimal background. At least three independent measurements were performed for each isolated sample.
For detection of inflammasome signaling proteins in isolated EV, EV were resuspended in protein lysis buffer and resolved by immunoblotting as described in 15. Briefly, following lysis of the pellet proteins were resolved in 10-20% Criterion TGX Stain-Free precasted gels (Bio-Rad), using antibodies (1:1000 dilution) to NLRP3 (Novus Biologicals), caspase-1 (Novus Biologicals), ASC (Santa Cruz), IL-1beta (Cell Signaling), IL-18 (Abcam), CD81 (Thermo Scientific) and NCAM (Sigma). Quantification of band density was done using the UN-SCAN-IT gel 5.3 Software (Silk Scientific Corporation). Ten ul of sample was loaded. Chemilluminescence substrate (LumiGlo, Cell Signaling) in membranes was imaged using the ChemiDoc Touch Imaging System (BioRad).
Total protein in the Criterion TGX Stain-Free precasted gels was imaged using the ChemiDoc Touch Imaging System (BioRad) by placing the gel in the tray of the ChemiDoc Touch following protein transfer. The image was then adjusted in the screen to show the entirety of the gel and running the Stain-Free Blot setting in the application window.
Statistical comparisons between the Invitrogen and ExoQuick isolation procedures were done using a two-tailed student t-test.
EV were loaded onto formvar-carbon coated grids. A 10 ul drop of the sample was then placed on clean parafilm and the grid was floated (face-down) for 30 min. Subsequent steps were also performed by floating the grid on a 10 ul bubble. The EV-loaded grid was then rinsed with 0.1 M Millonig’s phosphate buffer (Electron Microscopy Sciences) for 5 min. Excess fluid was drained. Then the grid was placed into 2% glutaraldehyde for 5 min. Subsequent washes were done to remove excess glutaraldehyde by rinsing with 0.1 M Millonig’s phosphate buffer for 5 min followed by distilled water for 2 min seven times on seven different bubbles. The grid was then transferred to a 0.4% Uranyl Acetate solution for 5 min. Grids were allowed to dry for imaging. Images were acquired with a Joel JEM-1400 transmission electron microscope, at a voltage of 80 kV, and a digital Gatan camera.
Data were analyzed using Prism 7 software (GraphPad). Comparisons between groups for protein levels were carried by first identifying outliers followed by an unpaired t-test and then determining the area under the ROC curve, as well as the 95% confidence interval and the p-value (p-value of significance used was <0.05). Finally, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of each biomarker was obtained for a range of different cut-off points. Samples that yielded a protein value below the level of detection of the assay were not included in the analyses for that particular analyte.
Caspase-1, ASC and IL-18 are elevated in the serum of stroke patients: To determine the protein levels of inflammasome proteins in serum from stroke patients and control donors, serum samples were analyzed with a Simple Plex system. Protein levels of caspase-1, ASC and IL-18 were higher in the serum of stroke patients when compared to the control samples, whereas levels of IL-1 were not significantly different (
ASC as a serum biomarker of stroke: Higher levels of inflammasome proteins in serum from stroke patients may not be enough proof to show that inflammasome proteins are good biomarkers of stroke. Thus, an ROC analysis was performed (
Amount of protein loaded in Isolated EV from stroke patients: To calculate the amount of protein present in the isolated exosomes from serum samples, a BCA assay was performed from isolates obtained by the Invitrogen method and the EQ method. The data indicated that the EQ method was able to isolate more protein than the Invitrogen method (
To visualize how much protein was loaded in a gel during immunoblot analysis, the Stain-Free Blot setting of the ChemiDoc Touch Imaging System was used. The representative image in
Invitrogen’s kit and EQ isolate CD81- and NCAM-positive EV from the serum of patients with stroke: To determine if inflammasome proteins present in EV are promising biomarkers of stroke, EV from the serum of stroke patients was isolated. Two different techniques of EV isolation was used to identify the most suitable method to isolate, inflammasome-containing EV. In addition, the tetraspanin protein CD81, a marker of EV {Andreu, 2014 #33} as well as and neural cell adhesion molecule (NCAM) a marker of neuronal-derived EV was used to demonstrate that the isolated EV are brain derived {Vella, 2016 #36}. Accordingly, both methods, the one from Invitrogen and EQ, were able to isolate CD81- and (NCAM)-positive EV (
Electron microscopy was performed on the EV isolated by the two techniques and found that the Invitrogen kit gave more uniformed and round vesicles (
Invitrogen’s kit and EQ isolate inflammasome-positive EV from the serum of patients with stroke: It has been previously shown that inflammasome proteins are present in EV6. The levels of inflammasome protein expression was compared by the two different methods and found no statistical significant difference in NLPR3, caspase-1, ASC and IL-18 levels between the two different methods. However, the EQ method was able to isolate EV with higher levels of IL-1 beta than the Invitrogen method (see
ASC is elevated in EV isolated from the serum of stroke patients: EV from the serum of 16 aged-matched donors and the 16 stroke samples (
ASC in serum-derived EV is a good biomarker of stroke: To determine if inflammasome proteins in serum-derived EV can be viable biomarkers of stroke, an ROC analysis (see
In this example, it was shown that ASC is a reliable biomarker of stroke onset. The area under the curve (AUC) for ASC in serum was 0.9975 with a confidence interval between 0.9914 to 1.004. This AUC value was higher than the other inflammasome signaling proteins analyzed in this study: caspase-1 (0.75), IL-1beta (0.6111) and IL-18 (0.6675), indicating that ASC is a superior biomarker to the other inflammasome proteins that were looked at in this study. The cut-off point for ASC was 404.8 pg/ml with 100% sensitivity and a 96% specificity with the cohort of samples used. Importantly, the AUC was increased to 1 when analyzing serum-derived EV samples from a small subset of patients. Accordingly, the cut-off point for ASC in serum-derived EV was found to be 97.57 pg/ml.
In this study, the Invitrogen kit was able to provide better quality EV as visualized by electron microscopy and by NTA analysis of isolated vesicles, despite obtained higher levels of protein isolation with the EQ kit. Importantly, both methods were efficient at isolating EV containing inflammasome proteins
In conclusion, these studies highlight the potential of inflammasome proteins, particularly ASC as a biomarker of stroke in serum and serum-derived EV.
The following references are incorporated by reference in their entireties for all purposes.
1. Xu X and Jiang Y. The Yin and Yang of innate immunity in stroke. Biomed Res Int. 2014;2014:807978.
2. Neumann S, Shields NJ, Balle T, Chebib M and Clarkson AN. Innate Immunity and Inflammation Post-Stroke: An alpha7-Nicotinic Agonist Perspective. Int J Mol Sci. 2015;16:29029-46.
3. Brand FJ, 3rd, de Rivero Vaccari JC, Mejias NH, Alonso OF and de Rivero Vaccari JP. RIG-I contributes to the innate immune response after cerebral ischemia. J Inflamm (Lond). 2015;12:52.
4. Abulafia DP, de Rivero Vaccari JP, Lozano JD, Lotocki G, Keane RW and Dietrich WD. Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice. J Cereb Blood Flow Metab. 2009;29:534-44.
5. de Rivero Vaccari JP, Dietrich WD and Keane RW. Therapeutics targeting the inflammasome after central nervous system injury. Transl Res. 2016;167:35-45.
6. de Rivero Vaccari JP, Brand F, 3rd, Adamczak S, Lee SW, Perez-Barcena J, Wang MY, Bullock MR, Dietrich WD and Keane RW. Exosome-mediated inflammasome signaling after central nervous system injury. J Neurochem. 2016;136 Suppl 1:39-48.
7. Zhang ZG and Chopp M. Exosomes in stroke pathogenesis and therapy. J Clin Invest. 2016; 126:1190-7.
8. Ji Q, Ji Y, Peng J, Zhou X, Chen X, Zhao H, Xu T, Chen L and Xu Y. Increased Brain-Specific MiR-9 and MiR-124 in the Serum Exosomes of Acute Ischemic Stroke Patients. PLoS One. 2016;11:e0163645.
9. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
10. Whiteley W, Chong WL, Sengupta A and Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke. 2009;40:e380-9.
11. Bustamante A, Simats A, Vilar-Bergua A, Garcia-Berrocoso T and Montaner J. Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns. Neurotherapeutics. 2016;13:671-684.
12. Katan M and Elkind MS. Inflammatory and neuroendocrine biomarkers of prognosis after ischemic stroke. Expert Rev Neurother. 2011;11:225-39.
13. Adamczak S, Dale G, de Rivero Vaccari JP, Bullock MR, Dietrich WD and Keane RW. Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article. J Neurosurg. 2012;117:1119-25.
14. Brand FJ, 3rd, Forouzandeh M, Kaur H, Travascio F and de Rivero Vaccari JP. Acidification changes affect the inflammasome in human nucleus pulposus cells. J Inflamm (Lond). 2016; 13:29.
15. de Rivero Vaccari JC, Brand FJ, 3rd, Berti AF, Alonso OF, Bullock MR and de Rivero Vaccari JP. Mincle signaling in the innate immune response after traumatic brain injury. Journal of neurotrauma. 2015;32:228-36.
16. de Rivero Vaccari JP, Patel HH, Brand FJ, 3rd, Perez-Pinzon MA, Bramlett HM and Raval AP. Estrogen receptor beta signaling alters cellular inflammasomes activity after global cerebral ischemia in reproductively senescence female rats. J Neurochem. 2016;136:492-6.
17. de Rivero Vaccari JP, Dietrich WD and Keane RW. Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. J Cereb Blood Flow Metab. 2014;34:369-75.
18. de Rivero Vaccari JP, Dietrich WD and Keane RW. Therapeutics targeting the inflammasome after central nervous system injury. Translational research : the journal of laboratory and clinical medicine. 2015.
19. de Rivero Vaccari JP, Lotocki G, Alonso OF, Bramlett HM, Dietrich WD and Keane RW. Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J Cereb Blood Flow Metab. 2009;29:1251-61.
20. de Rivero Vaccari JP, Lotocki G, Marcillo AE, Dietrich WD and Keane RW. A molecular platform in neurons regulates inflammation after spinal cord injury. J Neurosci. 2008;28:3404-14.
21. Fann DY, Lee SY, Manzanero S, Tang SC, Gelderblom M, Chunduri P, Bernreuther C, Glatzel M, Cheng YL, Thundyil J, Widiapradja A, Lok KZ, Foo SL, Wang YC, Li YI, Drummond GR, Basta M, Magnus T, Jo DG, Mattson MP, Sobey CG and Arumugam TV. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis. 2013;4:e790.
22. Minkiewicz J, de Rivero Vaccari JP and Keane RW. Human astrocytes express a novel NLRP2 inflammasome. Glia. 2013;61:1113-21.
23. Sun X, Song X, Zhang L, Sun J, Wei X, Meng L and An J. NLRP2 is highly expressed in a mouse model of ischemic stroke. Biochem Biophys Res Commun. 2016;479:656-662.
24. Ma Q, Chen S, Hu Q, Feng H, Zhang JH and Tang J. NLRP3 inflammasome contributes to inflammation after intracerebral hemorrhage. Ann Neurol. 2014;75:209-19.
25. Fann DY, Lim YA, Cheng YL, Lok KZ, Chunduri P, Baik SH, Drummond GR, Dheen ST, Sobey CG, Jo DG, Chen CL and Arumugam TV. Evidence that NF-kappaB and MAPK Signaling Promotes NLRP Inflammasome Activation in Neurons Following Ischemic Stroke. Mol Neurobiol. 2017.
26. Zhang N, Zhang X, Liu X, Wang H, Xue J, Yu J, Kang N and Wang X. Chrysophanol inhibits NALP3 inflammasome activation and ameliorates cerebral ischemia/reperfusion in mice. Mediators Inflamm. 2014;2014:370530.
27. Mendis S, Davis S and Norrving B. Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke. 2015;46:e121-2.
28. Esenwa CC and Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol. 2016;12:594-604.
29. Ridker PM and Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med. 1998;46:391-5.
30. Rosenson RS and Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res. 2012;53:1767-82.
31. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM and Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005; 111:570-5.
33. Barber M, Langhome P, Rumley A, Lowe GD and Stott DJ. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke. 2004;35:1421-5.
34. Turaj W, Slowik A, Dziedzic T, Pulyk R, Adamski M, Strojny J and Szczudlik A. Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci. 2006;246:13-9.
35. Mathivanan S, Ji H and Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010;73:1907-20.
36. Le Pecq JB. Dexosomes as a therapeutic cancer vaccine: from bench to bedside. Blood Cells Mol Dis. 2005;35:129-35.
37. Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol. 2015;77:13-27.
38. Thery C, Zitvogel L and Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2:569-79.
39. Campos JH, Soares RP, Ribeiro K, Andrade AC, Batista WL and Torrecilhas AC. Extracellular Vesicles: Role in Inflammatory Responses and Potential Uses in Vaccination in Cancer and Infectious Diseases. J Immunol Res. 2015;2015:832057.
40. Hurley JH, Boura E, Carlson LA and Rozycki B. Membrane budding. Cell. 2010;143:875-87.
41. Thery C, Ostrowski M and Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581-93.
42. Vella LJ, Sharples RA, Nisbet RM, Cappai R and Hill AF. The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J. 2008;37:323-32.
43. Izquierdo-Useros N, Naranjo-Gomez M, Erkizia I, Puertas MC, Borras FE, Blanco J and Martinez-Picado J. HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse? PLoS Pathog. 2010;6:e1000740.
44. Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M and Wrana JL. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151:1542-56.
45. Robbins PD and Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014; 14:195-208.
46. Rekker K, Saare M, Roost AM, Kubo AL, Zarovni N, Chiesi A, Salumets A and Peters M. Comparison of serum exosome isolation methods for microRNA profiling. Clin Biochem. 2014;47:135-8.
47. Taylor DD, Zacharias W and Gercel-Taylor C. Exosome isolation for proteomic analyses and RNA profiling. Methods Mol Biol. 2011;728:235-46.
48. Caradec J, Kharmate G, Hosseini-Beheshti E, Adomat H, Gleave M and Guns E. Reproducibility and efficiency of serum-derived exosome extraction methods. Clin Biochem. 2014;47:1286-92.
As defined by the US Center for Disease Control (“CDC), a traumatic brain injury (“TBF”) is “a disruption in the normal function of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury.” Important to the care of patients with TBI is the need for biomarkers that can predict onset, exacerbation as well as response to treatment. Additionally, there is a need for a minimally invasive method of harvesting these biomarkers for analysis.
The inflammasome is a key mediator of the innate immune response that in the CNS was first described to mediate inflammation after spinal cord injury2. The inflammasome is a multiprotein complex involved in the activation of caspase-1 and the processing of the pro-inflammatory cytokines IL-10 and IL-183.
In this example, the expression level of inflammasome proteins in serum samples from patients with TBI are determined. Further, an examination of the sensitivity and specificity of inflammasome signaling proteins as biomarkers of TBI was examined.
In this study, serum samples were analyzed from 120 normal donors and 21 patients that were diagnosed with TBI. Samples were purchased from BioreclamationlVT: The normal donor group consisted of samples obtained from 60 male and 60 female donors in the age range of 20 to 70 years old. The age range in the TBI group consisted of samples obtained from patients in the age range of 24 to 64 years old. Additionally, twenty-one control cerebral spinal fluid (“CSF”) samples were obtained from BioreclamationIVT, 9 CSF samples were obtained from the cohort of patients.
Concentration of inflammasome proteins ASC, IL-1β and IL-18 in serum and CSF was analyzed using a Simple Plex and a Simple Plex Explorer software. Results shown correspond to the mean of each sample run in triplicates. It should be noted that any system/instrument known in the art can be used to measure the levels of proteins (e.g., inflammasome proteins) in bodily fluids. Samples were collected three times a day for the first 5 days since patients arrived to the hospital. Samples were analyzed for the 1st, 2nd collection (Day 1) as well as 4th and 6th collections (Day 2)
Prism 7 software (GraphPad) was used to analyze the data obtained from the Simple Plex Explorer Software. Comparisons between groups were carried after identifying outliers followed by determination of the area under the receiver operator characteristic (ROC) curve, as well as the 95% confidence interval (CI). The p-value of significance used was <0.05. Sensitivity and specificity of each biomarker was obtained for a range of different cut-off points. Samples that yielded a protein value below the level of detection of the assay were not included in the analyses for that analyte.
ROC curves are summarized as the area under the curve (AUC). A perfect AUC value is 1.0, where 100% of subjects in the population will be correctly classified as having TBI or not. In contrast, an AUC of 0.5 signifies that subjects are randomly classified as either positive or negative for TBI, which has no clinical utility. It has been suggested that an AUC between 0.9 to 1.0 applies to an excellent biomarker; from 0.8 to 0.9, good; 0.7 to 0.8 fair; 0.6 to 0.7, poor and 0.5 to 0.6, fail.5
Serum samples from TBI patients were analyzed and compared to serum from healthy/control individuals using a Simple Plex assay (Protein Simple) for the protein expression of the inflammasome signaling proteins caspase-1, ASC, IL-1β and IL-18 (
To then determine if these inflammasome signaling proteins have the potential to be reliable biomarkers for TBI pathology, the area under the curve (AUC) for caspase-1, ASC, EL-10 and IL-18 (
Table 10A-D: ROC analysis results for inflammasome signaling proteins Caspase-1 (Table 10A), ASC (Table 10B), IL-10 (Table 10C) and IL-18 (Table 10D) in serum including area, standard error (STD. ERROR), 95% confidence interval (CI) and p-value for collections 1st, 2nd, 4th and 6th.
Furthermore, the cut-off point for caspase-1 was 1.943 pg/ml with 94% sensitivity and 89% specificity (Table 11A). For ASC, the cut-off point was 451.3 pg/ml with 85% sensitivity and 99% specificity (Table 11B). Moreover, we found that in regards to caspase-1 for 100% sensitivity, the cut-off point was 1.679 pg/ml with 78% specificity. For ASC, the cut-off point was 153.4 pg/ml and a 19% specificity (see Table 16 (4th collection)). In the case of caspase-1, for 100% specificity, the cut-off point was 2.717 pg/ml with 78% sensitivity (see Table 15 (4th collection)). For ASC with 100% specificity, the cut-off point was 462.4 pg/ml with 85% sensitivity (see Table 16 (4th collection)). Thus, these findings indicate that caspase-1 and ASC are reliable serum biomarkers for TBI.
Table 11A-B: ROC analysis results for caspase-1 (Table 11A) and ASC (Table 11B) in serum including cut-off point in pg/ml, sensitivity and specificity, as well as positive and negative likelihood ratios (LR+/LR-).
TBI patients were separated according to their clinical outcomes; either favorable or unfavorable outcomes based on the Glasgow Outcome Scale-Extended (GOSE) in which patients with a score of 6 to 8 were considered to have favorable outcomes and those with a score of 1 to 4 were considered to have unfavorable outcomes (Table s 12A and 12B). It was found that the protein level of ASC was higher in the serum of TBI patients with unfavorable outcomes when compared to the samples obtained from patients with favorable outcomes (
To determine if ASC can be used as prognostic biomarkers of TBI, we determined the AUC for ASC at the 2nd (
Table 12A-B: ROC analysis results for ASC in serum for Favorable (Table 12A) vs Unfavorable (Table 12B) outcomes, including area, standard error (STD. ERROR), 95% confidence interval (CI), p-value (see Table 12A), cut-off point in pg/ml, sensitivity and specificity, as well as positive and negative likelihood ratios (LR+/LR-) (see Table 12B) for collections 1st, 2nd and 4th.
CSF samples from TBI patients were analyzed and compared to CSF from healthy/control individuals using a Simple Plex assay (Protein Simple) for the protein expression of the inflammasome signaling proteins ASC and IL-18 (
To then determine if these inflammasome signaling proteins have the potential to be reliable biomarkers for TBI pathology, the area under the curve (AUC) for ASC, and IL-18 (
Tables 13A and 13B: ROC analysis results for ASC (Table 13A) and IL-18 (Table 13B) in CSF including cut-off point in pg/ml, sensitivity and specificity, as well as positive and negative likelihood ratios (LR+/LR-).
Furthermore, the cut-off point for ASC, the cut-off point was 74.33 pg/ml with 100% sensitivity and 100% specificity (Table 14A and Table 17). For IL-18, the cut-off point was 2.722 pg/ml with 80% sensitivity and 68% specificity (Table 14B and Table 18). As shown in Table 18, in the case of IL-18, for 100% specificity, the cut-off point was 3.879 pg/ml with 60% sensitivity; for 100% sensitivity, the cut-off point was 1.358 pg/ml, with 16%specificity. Thus, these findings indicate that ASC and IL-18 are reliable serum biomarkers for TBI.
Table 14A-B: ROC analysis results for ASC (Table 14A) and IL-18 (Table 14B) in CSF including cut-off point in pg/ml, sensitivity and specificity, as well as positive and negative likelihood ratios (LR+/LR-).
In this study, a statistically significant higher level of ASC and caspase-1 was detected in the serum of TBI patients when compared to healthy subjects. In this study, we show that ASC and IL-18 are reliable biomarkers for TBI in CSF with AUC values of 1.0 and 0.84, respectively. Most importantly, since obtaining CSF is a very invasive procedure, then our findings on serum are even more applicable to the typical clinical setting. Accordingly, we found that the AUC values for ASC was 0.90 and for caspase-1, 0.93. Thus caspase-1 and ASC should be considered as biomarkers in the care of patients with brain injury.
Moreover, the data showed that when comparing patients with unfavorable outcomes to patients with favorable outcomes chronically after TBI, the AUC for ASC was 0.92; thus, highlighting the usefulness of ASC as a TBI biomarker in serum, and, in this case, as a predictive biomarker of brain injury.
Thus, based on these findings ASC and caspace-1 are both promising biomarkers with a high AUC value, a high sensitivity and high specificity in serum. Additionally, based on these findings, ASC and IL-18 are both promising biomarkers with a high AUC value, a high sensitivity and high specificity in CSF. Importantly, ASC as a biomarker for TBI with other diagnostic criteria may further increase the sensitivity of ASC as a biomarker for TBI beyond what is described in this example.
Importantly, in this study, ASC has been identified as a potential biomarker of TBI pathology with a high AUC value of 0.9448 and with sensitivities above 80% and a specificity of over 90%.
The following references are incorporated by reference in their entireties for all purposes.
1. Adamczak, S., Dale, G., De Rivero Vaccari, J.P., Bullock, M.R., Dietrich, W.D., and Keane, R.W.(2012). Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article. J Neurosurg 117, 1119-1125.
2. Brand, F.J., 3rd, Forouzandeh, M., Kaur, H., Travascio, F., and De Rivero Vaccari, J.P. (2016). Acidification changes affect the inflammasome in human nucleus pulposus cells. J Inflamm (Lond) 13, 29.
3. De Rivero Vaccari, J.P., Brand, F., 3rd, Adamczak, S., Lee, S.W., Perez-Barcena, J., Wang, M.Y., Bullock, M.R., Dietrich, W.D., and Keane, R.W. (2016). Exosome-mediated inflammasome signaling after central nervous system injury. J Neurochem 136 Suppl 1, 39-48.
4. Keane, R.W., Dietrich, W.D., and De Rivero Vaccari, J.P. (2018). Inflammasome Proteins As Biomarkers of Multiple Sclerosis. Front Neurol 9,135.
5. Xia J, Broadhurst DI, Wilson M and Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013;9:280-299.
A biomarker is a characteristic that can be measured objectively and evaluated as an indicator of normal or pathologic biological processes1. Important to the care of patients with MCI is the need for biomarkers that can predict onset, exacerbation as well as response to treatment. Additionally, there is a need for a minimally invasive method of harvesting these biomarkers for analysis.
In this example, samples were purchased from BioIVT. Sample donors were enrolled in the study “Prospective Collection of Samples for Research” sponsored by SeraTrials, LLC. with IRB number 20170439. Here, serum samples from 72 normal male and female donors in the age range of 50 and 68 as well as from 32 male and female patients diagnosed with MCI (Table 20) in the age range of 56 to 91 were analyzed.
Analysis of inflammasome protein (caspase-1, ASC, IL-1β and IL-18) concentration in serum samples from MCI and age-matched controls were performed using the Ella System (Protein System) as described in 2, 3.
Data obtained by the Simple Plex assay were analyzed with Prism 7 software (GraphPad). First, outliers were removed and receiver operating characteristics (ROC) were calculated, thus obtaining a 95% confidence interval, a standard deviation and a p-value. P-value of significance was considered at less than 0.05. A cut-off point was then obtained for a range of different specificities and sensitivities and their respective likelihood ratio2,3.
Serum samples from patients with MCI patients and aged-matched healthy donors were analyzed for the protein expression levels of ASC (
To determine if inflammasome signaling proteins can be used as biomarkers of MCI, the area under the curve (AUC) was determined for caspase-1 (
The following references are incorporated by reference in their entireties for all purposes.
1.) Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
2.) Brand FJ, 3rd, Forouzandeh M, Kaur H, Travascio F, & de Rivero Vaccari JP (2016) Acidification changes affect the inflammasome in human nucleus pulposus cells. J Inflamm (Lond) 13(1):29.
3.) Keane RW, Dietrich WD, & de Rivero Vaccari JP (2018) Inflammasome Proteins As Biomarkers of Multiple Sclerosis. Front Neurol 9:135.
Other subject matter contemplated by the present disclosure is set out in the following numbered embodiments:
1. A method of evaluating a patient suspected of having multiple sclerosis (MS), the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with MS, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having MS if the patient exhibits the presence of the protein signature.
2. The method of embodiment 1, wherein the patient is presenting with clinical symptoms consistent with MS.
3. The method of embodiment 1 or 2, wherein the MS is relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), or progressive-relapsing MS (PRMS).
4. The method of any one of the above embodiments, wherein the biological sample obtained from the patient is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
5. The method of any one of the above embodiments, wherein the level of the at least one inflammasome protein in the protein signature is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein in the protein signature.
6. The method of any one of the above embodiments, wherein the at least one inflammasome protein is interleukin 18 (IL-18), IL-1beta, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof.
7. The method of any of the above embodiments, wherein the at least one inflammasome protein comprises each of caspase-1, IL-18, IL-1beta and ASC.
8. The method of any one of embodiments 1-6, wherein the at least one inflammasome protein comprises ASC.
9. The method of any one of embodiments 5-8, wherein the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein.
10. The method of any one of the above embodiments, wherein the level of the at least one inflammasome protein in the protein signature is enhanced relative to the level of the at least one inflammasome protein in a biological sample obtained from a control.
11. The method of embodiment 10, wherein the biological sample obtained from the control is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
12. The method of embodiment 10 or 11, wherein the control is a healthy individual, wherein the healthy individual is an individual not presenting with clinical symptoms consistent with MS.
13. The method of any one of embodiments 10-12, wherein the at least one inflammasome protein comprises ASC, wherein the level of ASC is at least 50% higher than the level of ASC in the biological sample obtained from a control.
14. The method of any one of embodiments 1-9, wherein the level of the at least one inflammasome protein in the protein signature is enhanced relative to a pre-determined reference value or range of reference values.
15. The method of embodiment 14, wherein the biological sample obtained from patient is serum and the patient is selected as having MS with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%.
16. The method of embodiment 14 or 15, wherein the biological sample is serum and the patient is selected as having MS with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%.
17. The method of embodiment 14, wherein the biological sample is serum and the patient is selected as having MS with a sensitivity of at least 90% and a specificity of at least 80%.
18. The method of any one of embodiments 14-17, wherein the at least one inflammasome protein comprises ASC.
19. The method of embodiment 18, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Table 7.
20. The method of any one of embodiments 15-17, wherein the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
21. A method of evaluating a patient suspected of having suffered a stroke, the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with stroke or a stroke-related injury, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having suffered from a stroke if the patient exhibits the presence of the protein signature.
22. The method of embodiment 21, wherein the patient is presenting with clinical symptoms consistent with stroke, wherein the stroke is ischemic stroke, transient ischemic stroke or hemorrhagic stroke.
23. The method of embodiment 21 or 22, wherein the biological sample obtained from the patient is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
24. The method of any one of embodiments 21-23, wherein the level of the at least one inflammasome protein in the protein signature is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein in the protein signature.
25. The method of any one of embodiments 21-24, wherein the at least one inflammasome protein is interleukin 18 (IL-18), IL-1beta, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof.
26. The method of any of embodiments 21-25, wherein the at least one inflammasome protein comprises each of caspase-1, IL-18, IL-1beta and ASC.
27. The method of any one of embodiments 21-25, wherein the at least one inflammasome protein comprises ASC.
28. The method of any one of embodiments 25-27, wherein the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein.
29. The method of any one of embodiments 21-28, wherein the level of the at least one inflammasome protein in the protein signature is enhanced relative to the level of the at least one inflammasome protein in a biological sample obtained from a control.
30. The method of embodiment 29, wherein the biological sample obtained from the control is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
31. The method of embodiment 29 or 30, wherein the control is a healthy individual, wherein the healthy individual is an individual not presenting with clinical symptoms consistent with MS.
32. The method of any one of embodiments 29-31, wherein the at least one inflammasome protein comprises ASC, wherein the level of ASC in a serum sample obtained from the subject is at least 70% higher than the level of ASC in a serum sample obtained from a control.
33. The method of any one of embodiments 29-31, wherein the at least one inflammasome protein comprises ASC, wherein the level of ASC in a serum-derived EV sample obtained from the subject is at least 110% higher than the level of ASC in a serum-derived EV sample obtained from a control.
34. The method of any one of embodiments 21-28, wherein the level of the at least one inflammasome protein in the protein signature is enhanced relative to a pre-determined reference value or range of reference values.
35. The method of embodiment 34, wherein the biological sample obtained from patient is serum and the patient is selected as having suffered a stroke with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%.
36. The method of embodiment 34 or 35, wherein the biological sample is serum and the patient is selected as having suffered a stroke with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%.
37. The method of embodiment 34, wherein the biological sample is serum and the patient is selected as having suffered a stroke with a sensitivity of at least 100% and a specificity of at least 95%.
38. The method of any one of embodiments 35-37, wherein the at least one inflammasome protein comprises ASC.
39. The method of embodiment 38, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Table 8.
40. The method of embodiment 34, wherein the biological sample obtained from patient is serum-derived EVs and the patient is selected as having suffered a stroke with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%.
41. The method of embodiment 34 or 40, wherein the biological sample is serum-derived EVs and the patient is selected as having suffered a stroke with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%.
42. The method of embodiment 34, wherein the biological sample is serum-derived EVs and the patient is selected as having suffered a stroke with a sensitivity of at least 100% and a specificity of at least 100%.
43. The method of any one of embodiments 40-42, wherein the at least one inflammasome protein comprises ASC.
44. The method of embodiment 43, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Table 9.
45. The method of any one of embodiments 35-37 or 40-42, wherein the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
46. A method of treating a patient diagnosed with multiple sclerosis (MS), the method comprising administering a standard of care treatment for MS to the patient, wherein the diagnosis of MS was made by detecting an elevated level of at least one inflammasome protein in a biological sample obtained from the patient.
47. The method of embodiment 46, wherein the MS is relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), or progressive-relapsing MS (PRMS).
48. The method of embodiment 46 or 47, wherein the standard of care treatment is selected from therapies directed towards modifying disease outcome, managing relapses, managing symptoms or any combination thereof.
49. The method of embodiment 48, wherein the therapies directed toward modifying disease outcome are selected from beta-interferons, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, mitoxanthrone, ocrelizumab, alemtuzumab, daclizumab and natalizumab.
50. A method of treating a patient diagnosed with stroke or a stroke related injury, the method comprising administering a standard of care treatment for stroke or stroke-related injury to the patient, wherein the diagnosis of stroke or stroke-related injury was made by detecting an elevated level of at least one inflammasome protein in a biological sample obtained from the patient.
51. The method of embodiment 50, wherein the stroke is ischemic stroke, transient ischemic stroke or hemorrhagic stroke.
52. The method of embodiment 50 or 51, wherein the stroke is ischemic stroke or transient ischemic stroke and the standard of care treatment is selected from tissue plasminogen activator (tPA), antiplatelet medicine, anticoagulants, a carotid artery angioplasty, carotid endarterectomy, intra-arterial thrombolysis and mechanical clot removal in cerebral ischemia (MERCI) or a combination thereof.
53. The method of embodiment 50 or 51, wherein the stroke is hemorrhagic stroke and the standard of care treatment is an aneurysm clipping, coil embolization or arteriovenous malformation (AVM) repair.
54. The method of any one of embodiments 46-53, wherein the elevated level of the at least one inflammasome protein is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein.
55. The method of any one of embodiments 46-54, wherein the level of the at least one inflammasome protein is enhanced relative to the level of the at least one inflammasome protein in a control sample.
56. The method of any one of embodiments 46-54, wherein the level of the at least one inflammasome protein is enhanced relative to a pre-determined reference value or range of reference values.
57. The method of any one of embodiments 46-56, wherein the at least one inflammasome protein is interleukin 18 (IL-18), apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof.
58. The method of embodiment 56 or 57, wherein the at least one inflammasome protein is caspase-1, IL-18, and ASC.
59. The method of embodiment 56 or 57, wherein the at least one inflammasome protein is ASC.
60. The method of embodiment 59, wherein the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein.
61. The method of any one of embodiments 46-60, wherein the biological sample is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
62. A method of evaluating a patient suspected of having traumatic brain injury (TBI), the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with TBI, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having TBI if the patient exhibits the presence of the protein signature.
63. The method of embodiment 62, wherein the patient is presenting with clinical symptoms consistent with TBI.
64. The method of embodiment 62 or 63, wherein the biological sample obtained from the patient is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
65. The method of any one of embodiments 62-64, wherein the level of the at least one inflammasome protein in the protein signature is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein in the protein signature.
66. The method of any one of embodiments 62-65, wherein the at least one inflammasome protein is interleukin 18 (IL-18), IL-1β, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof.
67. The method of any one of embodiments 61-66, wherein the at least one inflammasome protein comprises caspase-1.
The method of any one of embodiments 65-67, wherein the at least one inflammasome protein comprises caspase-1, wherein the level of caspase-1is at least 50% higher than the level of caspase-1in the biological sample obtained from a control.
68. The method of any one of embodiments 61-66, wherein the at least one inflammasome protein comprises ASC.
69. The method of any one of embodiments 66 or 68, wherein the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein.
70. The method of any one of embodiments 62-69, wherein the level of the at least one inflammasome protein in the protein signature is enhanced relative to the level of the at least one inflammasome protein in a biological sample obtained from a control.
71. The method of embodiment 70, wherein the at least one inflammasome protein comprises caspase-1, wherein the level of caspase-1 is at least 50% higher than the level of caspase-1in the biological sample obtained from the control.
72. The method of embodiment 70, wherein the at least one inflammasome protein comprises ASC, wherein the level of ASC is at least 50% higher than the level of ASC in the biological sample obtained from athe control.
73. The method of any one of embodiments 70-72, wherein the biological sample obtained from the control is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
74. The method of any one of embodiments 70-73, wherein the control is a healthy individual, wherein the healthy individual is an individual not presenting with clinical symptoms consistent with TBI.
75. The method of any one of embodiments 62-69, wherein the level of the at least one inflammasome protein in the protein signature is enhanced relative to a pre-determined reference value or range of reference values.
76. The method of embodiment 75, wherein the biological sample obtained from patient is serum and the patient is selected as having TBI with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%.
77. The method of embodiment 75 or 76, wherein the biological sample is serum and the patient is selected as having TBI with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%.
78. The method of embodiment 75, wherein the biological sample is serum and the patient is selected as having TBI with a sensitivity of at least 90% and a specificity of at least 80%.
79. The method of any one of embodiments 76-76, wherein the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
80. The method of any one of embodiments 75-79, wherein the at least one inflammasome protein comprises ASC.
81. The method of embodiment 79, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Tables 11B, 12B, 14A, 16, 17 or 19.
82. The method of any one of embodiments 75-79, wherein the at least one inflammasome protein comprises caspase-1.
83. The method of embodiment 82, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Tables 11A or 15.
84. A method of evaluating a patient suspected of having a brain injury, the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with brain injury, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having brain injury if the patient exhibits the presence of the protein signature.
85. The method of embodiment 84, wherein the patient is presenting with clinical symptoms consistent with brain injury.
86. The method of embodiment 84 or 85, wherein the biological sample obtained from the patient is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
87. The method of any one of embodiments 84-86, wherein the level of the at least one inflammasome protein in the protein signature is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein in the protein signature.
88. The method of any one of embodiments 84-87, wherein the at least one inflammasome protein is interleukin 18 (IL-18), IL-1β, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof.
89. The method of any one of embodiments 84-88, wherein the at least one inflammasome protein comprises ASC.
90. The method of embodiment 88 or 89, wherein the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein.
91. The method of any of embodiments 84-88, wherein the at least one inflammasome protein comprises caspase-1.
92. The method of any one of embodiments 84-91, wherein the level of the at least one inflammasome protein in the protein signature is enhanced relative to the level of the at least one inflammasome protein in a biological sample obtained from a control.
93. The method of embodiment 92, wherein the at least one inflammasome protein comprises ASC, wherein the level of ASC is at least 50% higher than the level of ASC in the biological sample obtained from the control.
94. The method of embodiment 92, wherein the at least one inflammasome protein comprises caspase-1, wherein the level of caspase-1 is at least 50% higher than the level of caspase-1in the biological sample obtained from the control.
95. The method of any one of embodiments 92-94, wherein the biological sample obtained from the control is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
96. The method of any one of embodiments 92-95, wherein the control is a healthy individual, wherein the healthy individual is an individual not presenting with clinical symptoms consistent with brain injury.
97. The method of any one of embodiments 84-96, wherein the brain injury is selected from a traumatic brain injury, stroke, mild cognitive impairment or multiple sclerosis.
98. The method of any one of embodiments 84-91, wherein the level of the at least one inflammasome protein in the protein signature is enhanced relative to a pre-determined reference value or range of reference values.
99. The method of embodiment 98, wherein the brain injury is traumatic brain injury (TBI).
100. The method of embodiment 99, wherein the biological sample obtained from patient is serum and the patient is selected as having TBI with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%.
101. The method of embodiment 98 or 99, wherein the biological sample is serum and the patient is selected as having TBI with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%.
102. The method of embodiment 99, wherein the biological sample is serum and the patient is selected as having TBI with a sensitivity of at least 90% and a specificity of at least 80%.
103. The method of any one of embodiments 100-102, wherein the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
104. The method of any one of embodiments 99-103, wherein the at least one inflammasome protein comprises ASC.
105. The method of embodiment 104, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Tables 11B, 12B, 14A, 16, 17 or 19.
106. The method of any one of embodiments 99-103, wherein the at least one inflammasome protein comprises caspase-1.
107. The method of embodiment 106, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Tables 11A or 15.
108. The method of embodiment 98, wherein the brain injury is multiple sclerosis (MS).
109. The method of embodiment 108, wherein the biological sample obtained from patient is serum and the patient is selected as having MS with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%.
110. The method of embodiment 108 or 109, wherein the biological sample is serum and the patient is selected as having MS with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%.
111. The method of embodiment 108, wherein the biological sample is serum and the patient is selected as having MS with a sensitivity of at least 90% and a specificity of at least 80%.
112. The method of any one of embodiments 108-111, wherein the at least one inflammasome protein comprises ASC.
113. The method of embodiment 112, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Table 7.
114. The method of any one of embodiments 109-113, wherein the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
115. The method of embodiment 98, wherein the brain injury is stroke.
116. The method of embodiment 115, wherein the biological sample obtained from patient is serum and the patient is selected as having suffered a stroke with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%.
117. The method of embodiment 115 or 116, wherein the biological sample is serum and the patient is selected as having suffered a stroke with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%.
118. The method of embodiment 115, wherein the biological sample is serum and the patient is selected as having suffered a stroke with a sensitivity of at least 100% and a specificity of at least 95%.
119. The method of any one of embodiments 116-118, wherein the at least one inflammasome protein comprises ASC.
120. The method of embodiment 119, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Table 8.
121. The method of embodiment 115, wherein the biological sample obtained from patient is serum-derived EVs and the patient is selected as having suffered a stroke with a sensitivity of at least 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 90%.
122. The method of embodiment 115 or 121, wherein the biological sample is serum-derived EVs and the patient is selected as having suffered a stroke with a specificity of at least 80%, 85%, 90%, 95%, 99% or 100%.
123. The method of embodiment 115, wherein the biological sample is serum-derived EVs and the patient is selected as having suffered a stroke with a sensitivity of at least 100% and a specificity of at least 100%.
124. The method of any one of embodiments 121-123, wherein the at least one inflammasome protein comprises ASC.
125. The method of embodiment 124, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Table 9.
126. The method of any one of embodiments 116-118 or 121-123, wherein the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
127. A method of evaluating a patient suspected of having mild cognitive impairment (MCI) the method comprising: measuring the level of at least one inflammasome protein in a biological sample obtained from the patient; determining the presence or absence of a protein signature associated with MCI, wherein the protein signature comprises an elevated level of the at least one inflammasome protein; and selecting the patient as having MCI if the patient exhibits the presence of the protein signature.
128. The method of embodiment 127, wherein the patient is presenting with clinical symptoms consistent with MCI.
129. The method of embodiment 127 or 128, wherein the biological sample obtained from the patient is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
130. The method of any one of embodiments 127-129, wherein the level of the at least one inflammasome protein in the protein signature is measured by an immunoassay utilizing one or more antibodies directed against the at least one inflammasome protein in the protein signature.
131. The method of any one of embodiments 127-130, wherein the at least one inflammasome protein is interleukin 18 (IL-18), IL-1β, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, or combinations thereof.
132. The method of any one of embodiments 127-131, wherein the at least one inflammasome protein comprises ASC.
133. The method of any one of embodiments 127-131, wherein the at least one inflammasome protein comprises IL-18.
134. The method of any one of embodiments 131-132, wherein the antibody binds to the PYRIN-PAAD-DAPIN domain (PYD), C-terminal caspase-recruitment domain (CARD) domain or a portion of the PYD or CARD domain of the ASC protein.
135. The method of any one of embodiments 127-134, wherein the level of the at least one inflammasome protein in the protein signature is enhanced relative to the level of the at least one inflammasome protein in a biological sample obtained from a control.
136. The method of embodiment 135, wherein the at least one inflammasome protein comprises ASC, wherein the level of ASC is at least 50% higher than the level of ASC in the biological sample obtained from the control.
137. The method of embodiment 135, wherein the at least one inflammasome protein comprises IL-18, wherein the level of IL-18 is at least 25% higher than the level of IL-18 in the biological sample obtained from the control.
138. The method of any one of embodiments 135-137, wherein the biological sample obtained from the control is cerebrospinal fluid (CSF), CNS microdialysate, saliva, serum, plasma, urine or serum-derived extracellular vesicles (EVs).
139. The method of any one of embodiments 135-138, wherein the control is a healthy individual, wherein the healthy individual is an individual not presenting with clinical symptoms consistent with MCI.
140. The method of any one of embodiments 127-134, wherein the level of the at least one inflammasome protein in the protein signature is enhanced relative to a pre-determined reference value or range of reference values.
141. The method of embodiment 140, wherein the biological sample obtained from patient is serum and the patient is selected as having MCI with a sensitivity of at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% and a specificity of at least 55%.
142. The method of embodiment 140 or 141, wherein the biological sample is serum and the patient is selected as having MCI with a sensitivity of at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100%.
143. The method of embodiment 140, wherein the biological sample is serum and the patient is selected as having MCI with a sensitivity of at least 70% and a specificity of at least 55%.
144. The method of any one of embodiments 140-143, wherein the sensitivity and/or sensitivity is determined using the area under curve (AUC) from receiver operator characteristic (ROC) curves with confidence intervals of 95%.
145. The method of any one of embodiments 140-144, wherein the at least one inflammasome protein comprises ASC.
146. The method of embodiment 145, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Table 22.
147. The method of any one of embodiments 140-144, wherein the at least one inflammasome protein comprises IL-18.
148. The method of embodiment 147, wherein a cut-off value for determining the sensitivity, specificity or both is selected from Table 22.
The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent application, foreign patents, foreign patent application and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, application and publications to provide yet further embodiments.
These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.
This application is a continuation of U.S. Application No. 16/648,839, filed on Mar. 19, 2020, which is a national phase of International Application No. PCT/US2018/051899, filed Sep. 20, 2018, which claims the benefit of priority to U.S. Provisional Application No. 62/696,549 filed Jul. 11, 2018, and U.S. Provisional Application No. 62/560,963 filed Sep. 20, 2017, the contents of each of which are hereby is incorporated by reference in its their entirety for all purposes.
This invention was made with U.S. government support under grant numbers 5R42NS086274-03 and NS086274 awarded by the National Institute of Health. The U.S. government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 62696549 | Jul 2018 | US | |
| 62560963 | Sep 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16648839 | Mar 2020 | US |
| Child | 17812058 | US |
